cvm_10q.htm

0001654954-23-006371.txt : 20230512 0001654954-23-006371.hdr.sgml : 20230512 20230512161155 ACCESSION NUMBER: 0001654954-23-006371 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230512 DATE AS OF CHANGE: 20230512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 23915787 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 10-Q 1 cvm_10q.htm FORM 10-Q cvm_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to ______________.

Commission File Number 001-11889

CEL-SCI CORPORATION

Colorado		84-0916344
State or other jurisdiction incorporation		(IRS) Employer Identification Number

8229 Boone Boulevard, Suite 802

Vienna, Virginia 22182

Address of principal executive offices

(703) 506-9460

Registrant's telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock		CVM		NYSE American

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Class of Stock		No. Shares Outstanding		Date
Common		44,714,679		May 8, 2023

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

Item 1.		Page

	Condensed Balance Sheets at March 31, 2023 (unaudited) and September 30, 2022	3

	Condensed Statements of Operations for the six months ended March 31, 2023 and 2022 (unaudited)	4

	Condensed Statements of Operations for the three months ended March 31, 2023 and 2022 (unaudited)	5

	Condensed Statement of Stockholders’ Equity for the three and six months ended March 31, 2023 and 2022 (unaudited)	6

	Condensed Statements of Cash Flows for the six months ended March 31, 2023 and 2022 (unaudited)	8

	Notes to Condensed Financial Statements (unaudited)	10

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures about Market Risks	25

Item 4.	Controls and Procedures	25

PART II

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26

Item 6.	Exhibits	26

	Signatures	27

Tacle of Contents

CEL-SCI CORPORATION
CONDENSED BALANCE SHEETS

	MARCH 31,			SEPTEMBER 30,
ASSETS	2023			2022
	(UNAUDITED)
Current assets:
Cash and cash equivalents	$	10,046,344		$	22,672,138
Prepaid expenses		598,377			762,063
Supplies used for R&D and manufacturing		1,893,683			2,001,715
Deposits		35,622			-

Total current assets		12,574,026			25,435,916

Finance lease right of use assets		10,034,892			10,937,797
Operating lease right of use assets		1,793,399			1,884,464
Property and equipment, net		11,179,697			11,889,029
Patent costs, net		192,231			212,201
Deposits		2,319,101			-
Supplies used for R&D and manufacturing		101,897			164,299

Total assets	$	38,195,243		$	50,523,706

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable	$	1,888,911		$	1,618,290
Accrued expenses		1,064,007			842,492
Due to employees		509,286			471,488
Lease liabilities, current portion		1,849,749			1,731,481

Total current liabilities		5,311,953			4,663,751

Finance lease obligations, net of current portion		10,855,289			11,721,368
Operating lease obligations, net of current portion		1,755,401			1,850,380
Other liabilities		125,000			125,000

Total liabilities		18,047,643			18,360,499

Commitments and contingencies

STOCKHOLDERS' EQUITY
Preferred stock, $0.01 par value; 200,000 shares authorized; 0 shares issued and outstanding		-			-
Common stock, $0.01 par value; 600,000,000 shares authorized; 43,787,825 and 43,448,317 shares issued and outstanding at March 31, 2023 and September 30, 2022, respectively		437,878			434,484
Additional paid-in capital		490,803,133			486,625,816
Accumulated deficit		(471,093,411	)		(454,897,093	)

Total stockholders' equity		20,147,600			32,163,207

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	38,195,243		$	50,523,706

See notes to condensed financial statements.

Tacle of Contents

CEL-SCI CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
SIX MONTHS ENDED MARCH 31, 2023 and 2022
(UNAUDITED)

	2023			2022

Operating expenses:
Research and development	$	11,476,034		$	12,606,984
General and administrative		4,350,761			5,788,250
Total operating expenses		15,826,795			18,395,234

Operating loss		(15,826,795	)		(18,395,234	)

Gain on derivative instruments		-			366,791
Other non-operating losses		-			(30,793	)
Interest expense, net		(311,852	)		(546,862	)
Other expense		(57,671	)		-

Net loss		(16,196,318	)		(18,606,098	)
Modification of warrants		(171,552	)		-

Net loss available to common shareholders	$	(16,367,870	)	$	(18,606,098	)

Net loss per common share – basic and diluted	$	(0.38	)	$	(0.43	)
Weighted average common shares outstanding – basic and diluted		43,513,571			43,100,070

See notes to condensed financial statements.

Tacle of Contents

CEL-SCI CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 2023 and 2022
(UNAUDITED)

	2023			2022

Operating expenses:
Research and development	$	6,083,488		$	6,523,817
General and administrative		2,092,758			3,028,042
Total operating expenses		8,176,246			9,551,859

Operating loss		(8,176,246	)		(9,551,859	)

Gain on derivative instruments		-			2,195
Interest expense, net		(159,063	)		(273,828	)
Other expense		(7,500	)		-

Net loss		(8,342,809	)		(9,823,492	)

Net loss available to common shareholders	$	(8,342,809	)	$	(9,823,492	)

Net loss per common share – basic and diluted	$	(0.19	)	$	(0.23	)
Weighted average common shares outstanding – basic and diluted		43,588,381			43,122,671

See notes to condensed financial statements.

Tacle of Contents

CEL-SCI CORPORATION

STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

					Additional
	Common Stock				Paid-In		Accumulated
	Shares		Amount		Capital		Deficit		Total

BALANCES AT SEPTEMBER 30, 2022		43,448,317		434,484		486,625,816		(454,897,093)		32,163,207

Warrant exercises		217,752		2,177		445,114		-		447,291
Equity based compensation - employees		-		-		1,703,931		-		1,703,931
401(k) contributions paid in common stock		21,331		213		49,965		-		50,178
Stock and options issued to nonemployees for service		40,236		402		91,221		-		91,623
2014 Incentive Stock Forfeited		(2,000)		(20)		(11,080)		-		(11,100)
Net loss		-		-		-		(7,853,509)		(7,853,509)

BALANCES AT DECEMBER 31, 2022		43,725,636		437,256		488,904,967		(462,750,602)		26,591,621

Equity based compensation - employees		-		-		1,743,288		-		1,743,288
401(k) contributions paid in common stock		23,627		236		54,629		-		54,865
Stock and options issued to nonemployees for service		38,562		386		100,249		-		100,635
Net loss		-		-		-		(8,342,809)		(8,342,809)

BALANCES AT MARCH 31, 2023		43,787,825		437,878		490,803,133		(471,093,411)		20,147,600

See notes to condensed financial statements.

Tacle of Contents

					Additional
	Common Stock				Paid-In			Accumulated
	Shares		Amount		Capital			Deficit			Total

BALANCES AT SEPTEMBER 30, 2021		43,207,183		432,072		474,298,566			(418,196,412	)		56,534,226

Warrant exercises		19,705		197		157,757			-			157,954
Equity based compensation - employees		-		-		3,262,296			-			3,262,296
401(k) contributions paid in common stock		7,605		76		52,479			-			52,555
Stock and options issued to nonemployees for service		18,020		180		142,980			-			143,160
Option exercises		6,500		65		29,770			-			29,835
Share issuance costs		-		-		(45,965	)		-			(45,965	)
Net loss		-		-		-			(8,782,606	)		(8,782,606	)

BALANCES AT DECEMBER 31, 2021		43,259,013		432,590		477,897,883			(426,979,018	)		51,351,455

Warrant exercises		5,500		55		13,805			-			13,860
Equity based compensation - employees		-		-		3,392,706			-			3,392,706
401(k) contributions paid in common stock		14,614		146		57,371			-			57,517
Stock and options issued to nonemployees for service		25,475		255		139,797			-			140,052
Share issuance costs		-		-		(4,550	)		-			(4,550	)
Net loss		-		-		-			(9,823,492	)		(9,823,492	)

BALANCES AT MARCH 31, 2022		43,304,602		433,046		481,497,012			(436,802,510	)		45,127,548

See notes to condensed financial statements.

Tacle of Contents

CEL-SCI CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
SIX MONTHS ENDED MARCH 31, 2023 and 2022
(UNAUDITED)

	2023			2022

Net loss	$	(16,196,318	)	$	(18,606,098	)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization		1,973,982			1,867,192
Non-cash lease expense		9,545			43,594
Share-based payments for services		285,722			402,270
Equity-based compensation		3,436,119			6,655,002
Common stock contributed to 401(k) plan		105,043			110,072
Gain on short-term investments		-			(615	)
Loss on patent impairment		-			30,793
Gain on derivative instruments		-			(366,791	)
Loss on Receivables		-			54,922
(Increase)/decrease in assets:
Prepaid expenses		180,222			2,552
Supplies used for R&D and manufacturing		170,434			1,288
Deposits		(2,354,723	)		1,910,917
Increase/(decrease) in liabilities:
Accounts payable		102,841			46,033
Accrued expenses		111,515			89,149
Due to employees		37,798			222,112

Net cash used in operating activities		(12,137,820	)		(7,537,608	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from maturity of US treasury bills		-			6,152,000
Purchases of property and equipment		(165,032	)		(550,861	)
Expenditures for patent costs		-			(22,741	)

Net cash (used in) provided by investing activities		(165,032	)		5,578,398

CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of stock issuance costs		(9,010	)		(45,965	)
Proceeds from exercises of warrants		447,291			101,225
Proceeds from the exercises of options		-			29,835
Proceeds from landlord funding of lease improvements		-			786,454
Payments on obligations under finance leases		(761,223	)		(689,615	)

Net cash (used in) provided by financing activities		(322,942	)		181,934

NET DECREASE IN CASH AND CASH EQUIVALENTS		(12,625,794	)		(1,777,276	)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		22,672,138			36,060,148

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	10,046,344		$	34,282,872

See notes to condensed financial statements.

Tacle of Contents

CEL-SCI CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
SIX MONTHS ENDED MARCH 31, 2023 and 2022

	2023		2022
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment purchases included in current liabilities	$	176,743	$	32,549
Finance lease obligation included in accounts payable	$	1,402	$	374
Prepaid consulting services paid with issuance of common stock	$	192,258	$	354,853
Exercise of derivative liabilities	$	-	$	70,589
Modification of finance leases	$	-	$	16,268
Financing costs included in current liabilities	$	-	$	4,550
Accrued consulting services to be paid with common stock	$	165,000	$	165,000

Cash paid for interest	$	547,765	$	578,837

See notes to condensed financial statements.

Tacle of Contents

CEL-SCI CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

SIX MONTHS ENDED MARCH 31, 2023 AND 2022 (UNAUDITED)

A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2022.

In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary for a fair presentation of the Company’s financial position as of March 31, 2023 and the results of its operations for the six months then ended. The condensed balance sheet as of September 30, 2022 is derived from the September 30, 2022 audited financial statements.

Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.

Summary of Significant Accounting Policies:

Cash and Cash Equivalents – Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash and cash equivalents.

U.S. Treasury Bills – U.S. Treasury Bills (“T-bills”) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.

Property and Equipment – Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.

Supplies used for R&D and manufacturing – Supplies are consumable items kept on hand to support the Company’s R&D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Leases – The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.

Tacle of Contents

Derivative Instruments – The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, Accounting for Derivative Instruments and Hedging Activities. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.

The Company adopted Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in an Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity effective October 1, 2021. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. There was no financial impact in the period of adoption.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, Compensation – Stock Compensation. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period.

The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company’s stockholders.

The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.

Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.

Tacle of Contents

Net Loss Per Common Share – The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

Income Taxes – The Company accounts for income taxes in accordance with the provisions of ASC 740, "Income Taxes" ("ASC 740"), on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of March 31, 2023 and September 30, 2022.

The Company adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company’s financial statements.

Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes option pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.

New Accounting Pronouncements - The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

B. LIQUIDITY

The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from the U.S. Food and Drug Administration (FDA) for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings similar to the way it has funded operations in the past. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.

Tacle of Contents

To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because it showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.

Due to the Company’s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

C. STOCKHOLDERS’ EQUITY

Equity Compensation

Underlying share information for equity compensation plans as of March 31, 2023 is as follows:

Name of Plan	Total Shares Reserved Under Plans

Incentive Stock Option Plans		138,400
Non-Qualified Stock Option Plans		13,787,200
Stock Bonus Plans		783,760
Stock Compensation Plans		634,000
Incentive Stock Bonus Plan		640,000

Stock option activity:

	Six Months Ended March 31,
	2023		2022
Options granted		4,500		252,500
Options exercised		-		6,500
Options forfeited		122,332		20,166
Options expired		45,404		-

	Three Months Ended March 31,
	2023		2022
Options granted		2,000		1,500
Options exercised		-		-
Options forfeited		25,500		7,166
Options expired		4		-

During the quarter ended December 31, 2021, the Company granted 250,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers. Each option entitles the holder to purchase one share of the Company’s common stock at a price of $10.48 per share, the fair value on the date of issuance. The stock options will vest 100% upon approval of the first marketing application for any pharmaceutical based upon the Company’s Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. All options which have not vested as of November 18, 2031 will be canceled. On the grant date, the options were valued using a Monte Carlo Simulation approach. A Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. However, because attainment of the performance condition cannot be considered probable, no compensation cost was recognized relating to these options as of March 31, 2023. Management will re-assess the probability of achieving the performance condition at each reporting date.

Tacle of Contents

Stock-Based Compensation Expense

	Six months Ended March 31,
	2023		2022
Employees	$	3,436,119	$	6,655,002
Non-employees	$	285,722	$	402,270

	Three months Ended March 31,
	2023		2022
Employees	$	1,743,288	$	3,392,706
Non-employees	$	136,864	$	183,952

Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts.

Warrants and Non-Employee Options

The following chart represents the warrants and non-employee options outstanding at March 31, 2023:

Warrant/ Options	Issue Date	Shares Issuable upon Exercise of Warrants/ Options	Exercise Price	Expiration Date	Reference
Series N	8/18/2008	85,339	$3.00	8/18/2024	*
Series UU	6/11/2018	93,603	$2.80	6/30/2024	*
Series X	1/13/2016	120,000	$9.25	7/13/2024	*
Series Y	2/15/2016	26,000	$12.00	8/15/2024	*
Series MM	6/22/2017	333,432	$1.86	6/22/2024	*
Series NN	7/24/2017	200,087	$2.52	7/24/2024	*
Series RR	10/30/2017	234,009	$1.65	10/30/2024	*
Series TT	2/5/2018	-	$2.24	2/5/2023	2
Consultant Options	7/28/2017	10,000	$2.18	7/27/2027	*

* No current period changes for these warrants

Tacle of Contents

1. Derivative Liabilities

The table below presents the gains on the warrant liabilities for the six months ended March 31:

	2023		2022
Series Z warrants	$	-	$	64,787
Series AA warrants		-		274,635
Series CC warrants		-		24,372
Series HH warrants		-		1,597
Net gain on warrant liabilities	$	-	$	366,791

The table below presents the gains on the warrant liabilities for the three months ended March 31:

	2023		2022
Series AA warrants	$	-	$	1,400
Series HH warrants		-		795
Net gain on warrant liabilities	$	-	$	2,195

The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded.

In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss.

Changes in Warrant Liabilities

As of March 31, 2023, no warrant liabilities were outstanding.

During the six months ended March 31, 2022, 15,205 Series CC warrants were exercised at an exercise price of $5.00 for gross proceeds of $76,025. No Series CC warrants were exercised during the three months ended March 31, 2022.

In February 2022, 100,000 Series AA warrants with, an exercise price of $13.75 and 200 Series HH warrants with an exercise price of $3.13, expired. In December 2021, 640 Series CC warrants, with an exercise price of $5.00, expired. In November 2021, 184,800 Series Z warrants, with an exercise price of $13.75, expired.

2. Equity Warrants

Changes in Equity Warrants

On February 5, 2023, 600 Series TT warrants, with an exercise price of $2.24, expired.

During the six months ended March 31, 2023, 17,752 Series RR warrants at an exercise price of $1.65 and 200,000 Series SS warrants at an exercise price of $2.09 were exercised for gross proceeds of $447,291. No series RR or SS warrants were exercised during the three months ended March 31, 2023.

During the six months ended March 31, 2022, 10,000 Series NN warrants were exercised at an exercise price of $2.52 for gross proceeds of $25,200. During the three months ended March 31, 2022, 5,500 Series NN warrants were exercised at an exercise price of $2.52 for gross proceeds of $13,860.

Tacle of Contents

On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary.

3. Options and Shares Issued to Consultants

During the six months ended March 31, 2023 and 2022, the Company issued 78,798 and 43,495 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $2.47 and $7.05 during the six months ended March 31, 2023 and 2022, respectively. During the three months ended March 31, 2023 and 2022, the Company issued 38,562 and 25,475 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $2.42 and $5.00, respectively, during the three months ended March 31, 2023 and 2022. The aggregate values of the issuances of restricted common stock and common stock options are recorded as prepaid expenses and are charged to general and administrative expenses over the periods of service.

During the six months ended March 31, 2023, 5,000 options with an exercise price of $11.61 issued to a consultant expired.

As of March 31, 2023, 10,000 options issued to consultants remained outstanding, all of which were issued from the Non-Qualified Stock Option plans. All 10,000 options are vested as of March 31, 2023.

During the six months ended March 31, 2023 and 2022, the Company recorded total expense of approximately $285,000 and $402,000, respectively, relating to the share-based compensation under these consulting agreements. On March 31, 2023 and September 30, 2022, consulting fees of approximately $311,000 and $295,000, respectively, are included in prepaid expenses and will be amortized over the remaining service periods.

D. FAIR VALUE MEASUREMENTS

In accordance with ASC 820-10, Fair Value Measurements, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.

ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:

	●	Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities

	●	Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets

	●	Level 3 – Unobservable inputs that reflect management’s assumptions. Assumptions from market participants are used when pricing the asset or liabilities, given there is no readily available market information.

For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of an input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.

Tacle of Contents

The following sets forth a reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for both the six and three months ended March 31, 2023 and 2022:

	Six months ended March 31, 2023		Six months ended March 31, 2022

Beginning balance	$	-	$	437,380
Issuances		-		-
Exercises		-		(70,589	)
Realized and unrealized (gains) and losses		-		(366,791	)
Ending balance	$	-	$	-

	Three months ended March 31, 2023		Three months ended March 31, 2022

Beginning balance	$	-	$	2,195
Issuances		-		-
Exercises		-
Realized and unrealized (gains) and losses		-		(2,195	)
Ending balance	$	-	$	-

The fair values of the Company’s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock, as well as U.S. Treasury Bill rates. At March 31, 2023 and September 30, 2022, the Company did not have any Level 3 derivative instruments.

E. RELATED PARTY TRANSACTIONS

On October 28, 2022, the expiration dates of the Series RR warrants held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary were extended by two years. The incremental cost of these modifications was $172,552 and was recorded as a deemed dividend in the financial statements for the six months ended March 31, 2023.

F. COMMITMENTS AND CONTINGENCIES

Clinical Research Agreement

Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company’s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808 “Collaborative Arrangements”. The Company determined the payments to Ergomed are within the scope of ASC 730 Research and Development. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.6 million for Ergomed’s services. This amount is net of Ergomed’s discount of approximately $11.8 million. During the six months ended March 31, 2023 and 2022, the Company recorded, net of Ergomed’s discount, approximately $0.1 million and $0.4 million, respectively, as research and development expense related to Ergomed’s services. During the three months ended March 31, 2023 and 2022, the Company recorded, net of Ergomed’s discount, approximately $0.0 million and $0.2 million, respectively, as research and development expense related to Ergomed’s services.

Tacle of Contents

Lease Agreements

The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.

On March 31, 2023 and September 30, 2022, the net book value of the finance lease right of use asset is approximately $10.0 million and $10.9 million, respectively and the balance of the finance lease liability is approximately $12.5 million and $13.3 million, respectively, of which approximately $1.6 million is current in each quarter. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the six months ended March 31, 2023 and 2022 was approximately $1.3 million for both periods, respectively, of which approximately $0.6 million was for interest in each six-month period. As of March 31, 2023, the weighted average discount rate of the Company’s finance leases is 8.45% and the weighted average time to maturity is 5.6 years.

In August 2020, the Company entered into an amendment to the San Tomas lease under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The project was finished and the improvements were placed in service in October 2021. Total cost was $11.1 million, of which the landlord agreed to finance $2.4 million. The landlord financing is being repaid through increased lease payments which started in March 2021 and extend over the remaining lease term. The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year. The Company remeasured the lease liability to account for the modified payments using a 8.45% implicit interest rate. The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist. Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized. The entire $2.4 million was received from the landlord as of September 30, 2022. The leasehold improvements are recorded in property and equipment, were deemed to be placed in service in October 2021 and are being amortized over the remaining lease term.

On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year’s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.

Approximate future minimum lease payments under finance leases as of March 31, 2023 are as follows:

Six months ending September 30, 2023	$	1,291,000
Year ending September 30,
2024		2,655,000
2025		2,741,000
2026		2,832,000
2027		2,923,000
2028		3,015,000
Thereafter		252,000
Total future minimum lease obligation		15,709,000
Less imputed interest on finance lease obligations		(3,189,000	)
Net present value of finance lease obligations	$	12,520,000

Tacle of Contents

The Company leases two facilities under operating leases. The lease for the Company’s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. This resulted in an increase of approximately $1.1 million to the operating lease right of use asset and liability. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. As of March 31, 2023 and September 30, 2022, the net book value of the operating lease right of use assets is approximately $1.8 million and $1.9 million, respectively. As of March 31, 2023 and September 30, 2022, the balance of the operating lease liabilities is approximately $1.9 million and $2.0 million, respectively, of which approximately $0.2 million, is current as of each reporting date. The Company incurred lease expense for operating leases of approximately $0.1 million and $0.2 million for the six months ended March 31, 2023 and 2022, respectively. Total cash paid related to operating leases during the six months ended March 31, 2023 and 2022 was approximately $0.2 and $0.1 million, respectively. The weighted average discount rate of the Company’s operating leases is 10.2% and the weighted average time to maturity is 8.14 years.

As of March 31, 2023, future minimum lease payments on operating leases are as follows:

Six months ending September 30, 2023	$	176,000
Year ending September 30,
2024		357,000
2025		366,000
2026		287,000
2027		277,000
2028		285,000
Thereafter		1,040,000
Total future minimum lease obligation		2,788,000
Less imputed interest on operating lease obligation		(849,000	)
Net present value of operating lease obligation	$	1,939,000

G. PATENTS

During the six months ended March 31, 2023 and 2022, the Company recorded approximately $0 and $31,000 in patent impairment charges. No patent impairment charges were recorded during the three months ended March 31, 2023 and 2022. For the six months ended March 31, 2023 and 2022, amortization of patent costs totaled approximately $20,000 and $27,000, respectively. For the three months ended March 31, 2023 and 2022, amortization of patent costs totaled approximately $10,000 and $13,000, respectively. Approximate estimated future amortization expense is as follows:

Six months ending September 30, 2023	$	18,000
Year ending September 30,
2024		30,000
2025		28,000
2026		24,000
2027		21,000
2028		17,000
Thereafter		54,000
Total	$	192,000

H. LOSS PER COMMON SHARE

Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period.

Tacle of Contents

The following tables provide the details of the basic and diluted loss per-share computations:

	Six months ended March 31,						Three months ended March 31,
	2023			2022			2023			2022
Loss per share – basic and diluted
Net loss available to common shareholders – basic and diluted	$	(16,367,869	)	$	(18,606,098	)	$	(8,342,809	)	$	(9,823,492	)
Weighted average shares outstanding – basic and diluted		43,513,571			43,100,070			43,588,381			43,122,671
Basic and diluted loss per common share	$	(0.38	)	$	(0.43	)	$	(0.19	)	$	(0.23	)

In accordance with the contingently issuable shares guidance of ASC Topic 260, Earnings Per Share, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of March 31:

	2023		2022

Options and Warrants		13,893,248		12,586,365
Unvested Restricted Stock		149,250		151,250
Total		14,042,498		12,737,615

J. SUBSEQUENT EVENTS

On April 27, 2023, the Company sold 794,117 shares of common stock at a public offering price of $1.70 per share and received aggregate net proceeds of approximately $1.1 million. The Company granted the underwriters a 30-day option to purchase up to 119,117 additional shares of common stock to cover over-allotments. The underwriter fully exercised this option on May 2, 2023 resulting in additional net proceeds to the Company of approximately $190,000.

Tacle of Contents

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

The Company has completed its 9.5 year pivotal Phase 3 study for its immunotherapy Multikine® (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). The results have been posted on www.clinicaltrials.gov. The Phase 3 study results showed a long-term 5-year overall survival (OS) benefit in the treatment arm that received Multikine treatment followed by surgery and radiation. This survival benefit was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5 years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), control arm 48.6%, Multikine arm 62.7% survival.

The study used the standard of care treatment for advanced primary head and neck cancer patients as a comparison. The patients received surgery followed by either radiation or chemoradiation (chemotherapy and radiation at the same time), as determined by the physician based on pathology from surgery. This meant that there were 2 distinctly different treatment arms, 1) surgery plus radiation or 2) surgery plus chemoradiation. The arm that received Multikine treatment followed by surgery and radiation showed great survival benefit, but when chemotherapy was added in the second treatment arm, the immunological effect of Multikine was negated. Therefore, when the two treatment arms were combined the study did not achieve its primary endpoint of a 10% improvement in overall survival.

The analysis of the separate treatment arms (radiation and chemoradiation) was prespecified in the protocol and carried out prior to the Company becoming unblinded. The OS benefit of 14.1% at 5 years for the surgery plus radiation treatment arm exceeded the 10% OS benefit set out for the study population as a whole. The OS results for this treatment arm are significant (two-sided p=0.0236, HR=0.68) and the effect is robust, durable and increasing over time, and advanced primary head and neck cancer represents an unmet medical need. The Company believes that these results for one treatment arm in the Phase 3 cancer study of Multikine are very meaningful and is working on the best way to bring Multikine to market in the United States and other countries.

Tacle of Contents

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.

The Company also owns and is developing a pre-clinical technology called LEAPS (Ligand Epitope Antigen Presentation System). The Company is using its LEAPS technology platform to investigate its lead peptide-based immunotherapy (CEL-4000) as a potential therapeutic vaccine treatment of rheumatoid arthritis.

All of the Company’s projects are under development. As a result, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Liquidity and Capital Resources

Since inception, the Company has financed its operations through the issuance of equity securities, convertible notes, loans and certain research grants. The Company will likely continue to generate net operating losses as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist the Company’s capital requirements.

Capital raised by the Company has been expended primarily for patent applications, research and development, administrative costs, and the construction and upgrade of the Company’s manufacturing and laboratory facilities. The Company does not anticipate realizing significant revenues until entering into licensing arrangements for its technology and know-how or until it receives regulatory approval to sell its products (which could take several years). Thus, the Company has been dependent upon the proceeds from the sale of its securities to meet all of the Company’s liquidity and capital requirements and anticipates having to do so in the future.

The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.

Since the Company launched its Phase 3 clinical trial for Multikine, the Company has incurred expenses of approximately $64.1 million as of March 31, 2023 on direct costs for the Phase 3 clinical trial and the filing of the clinical study report to the FDA. The Company estimates it will incur additional expenses of approximately $0.8 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report to the FDA. It should be noted that this estimate is based only on the information currently available from the CROs responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g., the manufacturing of the drug.

The Company uses two CROs to manage the global Phase 3 study; ICON and Ergomed, who are both international leaders in managing oncology trials.

Tacle of Contents

Under a co-development agreement, Ergomed agreed to contribute up to $12 million towards the study where it will perform clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount. Approximately $11.8 million of the committed $12 million contribution has been realized as of March 31, 2023.

During the six months ended March 31, 2023, the Company’s cash decreased by approximately $12.6 million. The significant component of this decrease included cash used to fund the Company’s regular operations of approximately $12.1 million, which includes the approximate $2.3 million deposit made to the Company’s landlord as a result of falling below certain cash requirements per the San Tomas lease. Other components of this decrease include approximately $0.2 million used to make leasehold improvements and acquire research and development equipment, and approximately $0.8 million in payments on the Company’s finance leases.

During the six months ended March 31, 2022, the Company used approximately $7.9 million in cash, after considering the maturity and transfer to cash of the remaining $6.2 million in U.S. Treasury bills (T-bills). Significant components of this decrease include cash used to fund the Company’s regular operations, including its Phase 3 clinical trial, of approximately $7.5 million, leasehold improvement costs of approximately $0.6 million and approximately $0.7 million in lease payments. These outflows are offset by approximately $0.8 million in lease incentives received from the landlord to partially offset costs of the manufacturing facility upgrade and approximately $0.1 million in proceeds from the exercise of options and warrants.

Prepaid expenses decreased by approximately $0.2 million, or 22%, at March 31, 2023 as compared to September 30, 2022 primarily due to a decrease in the amounts prepaid in personal property tax on the San Tomas facility.

During the six months ended March 31, 2023, 217,752 warrants were exercised at a weighted average exercise price of $2.05 for total proceed of approximately $0.5 million. During the six months ended March 31, 2022, 25,205 warrants were exercised at a weighted average exercise price of $4.02 for total proceeds of approximately $0.1 million.

Results of Operations and Financial Condition

The Company incurred a net operating loss of approximately $15.8 million for the six months ended March 31, 2023. This net operating loss consists of significant non-cash expenses including approximately $3.4 million in stock-based employee compensation and approximately $2.0 million in depreciation and amortization expense. The Company incurred a net operating loss of approximately $8.2 million for the three months ended March 31, 2023. This net operating loss consists of significant non-cash expenses including approximately $1.7 million in stock-based employee compensation and approximately $1.0 million in depreciation and amortization expense.

During the six months ended March 31, 2023, research and development expenses decreased by approximately $1.1 million, or 9%, compared to the six months ended March 31, 2022. Major components of this decrease include approximately $1.6 million decrease in employee stock compensation expense, and approximately $0.5 million decrease in expenses related to the Phase 3 study. These decreases were offset by an increase of approximately $0.9 million of costs incurred to prepare for the potential commercial sale of Multikine and a net increase of approximately $0.1 million in other research and development costs. During the three months ended March 31, 2023, research and development expenses decreased by approximately $0.4 million, or 7%, compared to the three months ended March 31, 2022. Major components of this decrease include approximately $0.8 million decrease in employee stock compensation expense and $0.1 million in costs related to the Phase 3 clinical study. These decreases are offset by increases in costs incurred to prepare for the potential commercial sale of Multikine of approximately $0.4 million and other research and development costs of approximately $0.1 million.

Tacle of Contents

During the six months ended March 31, 2023, general and administrative expenses decreased by approximately $1.4 million, or 25%, compared to the six months ended March 31, 2022. This decrease is primarily due to a decrease in employee stock compensation expense of approximately $1.6 million offset by a $0.2 million net increase in other general and administrative expenses. During the three months ended March 31, 2023, general and administrative expenses decreased by approximately $0.9 million, or 31%, compared to the three months ended March 31, 2022. A major component of the decrease is an approximate $0.9 million decrease in employee stock compensation expense.

During the six months ended March 31, 2023 and 2022, the Company recorded derivative gains of approximately $0 million and $0.4 million, respectively. This variation was the result of the change in fair value of the derivative liabilities during the period which was caused by fluctuations in the share price of the Company’s common stock. No derivative gains or losses were recorded during the three months ended March 31, 2023. During the three months ended March 31, 2022 the Company recorded a derivative gain of $2,195.

During the six months ended March 31, 2023, net interest expense decreased by approximately $0.2 million compared to the six months ended March 31, 2022. While the amount of interest paid on the Company’s lease liabilities, remained relatively constant at approximately $0.6 million for the six months ended March 31, 2023 and March 31, 2022, the Company earned approximately $0.2 million more in interest income during the six months ended March 31, 2023 compared to the six months ended March 31, 2022. During the three months ended March 31, 2023 net interest expense decreased by approximately $0.1 million compared to the three months ended March 31, 2022. While the amount of interest paid on the Company’s lease liabilities remained relatively constant at approximately $0.3 million for the three months ended March 31, 2023 and March 31, 2022, the company earned approximately $0.1 million more in interest income during the three months ended March 31, 2023 compared to the three months ended March 31, 2022.

Research and Development Expenses

The Company’s research and development efforts involve Multikine and LEAPS. The table below shows the research and development expenses associated with each project.

	Six months ended March 31,				Three months ended March 31,
	2023		2022		2023		2022

MULTIKINE	$	11,258,629	$	11,995,302	$	5,964,252	$	6,203,883
LEAPS		217,405		611,682		119,236		319,934

TOTAL	$	11,476,034	$	12,606,984	$	6,083,488	$	6,523,817

Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company’s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company’s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Critical Accounting Estimates and Policies

Management’s discussion and analysis of the Company’s financial condition and results of operations is based on its unaudited condensed financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes.

The Company believes some of the more critical estimates and policies that affect its financial condition and results of operations are in the areas of leases and stock-based compensation.

Tacle of Contents

The measurement of the finance and operating lease right-of-use asset and lease liabilities requires the determination of an estimated lease term and an incremental borrowing rate, which involves complex judgment by management. Significant judgment is required by management to develop inputs and assumptions used to determine the incremental borrowing rate for lease contracts. The fair value of the stock options is calculated using the Black-Scholes option pricing model which requires various judgmental assumptions including volatility and expected option life. The compensation cost is recognized as expense over the requisite service or vesting period. Performance-based options are valued using a Monte-Carlo simulation model, which requires inputs based on estimates, including the likelihood of the occurrence of performance and market conditions, volatility and expected option life.

For more information regarding the Company’s critical accounting estimates and policies, see Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended September 30, 2022. The application of these critical accounting policies and estimates has been discussed with the Audit Committee of the Company’s Board of Directors.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

The Company does not believe that it has any significant exposure to market risk.

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the direction and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, the Company carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of March 31, 2023. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and that such information is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives.

The Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were not effective as of March 31, 2023 due to the material weaknesses described in the Company's Annual Report on Form 10-K for the year ended September 30, 2022.

Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting that occurred during the three months ended March 31, 2023 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Tacle of Contents

PART II

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the six months ended March 31, 2023, the Company issued 78,798 restricted shares of common stock to consultants for investor relations services.

The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information regarding the Company’s business and operations. There was no general solicitation in connection with the offer or sale of these securities. The individuals who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend which provides they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.

Item 6. Exhibits

Number		Exhibit

31		Rule 13a-14(a) Certifications

32		Section 1350 Certifications

Tacle of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CEL-SCI CORPORATION

Date: May 12, 2023	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive Officer*

* Also signing in the capacity of the Principal Accounting and Financial Officer.

Tacle of Contents

EX-31 2 cvm_ex31.htm CERTIFICATION cvm_ex31.htm

EXHIBIT 31

CERTIFICATIONS

I, Geert Kersten, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

	d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 12, 2023	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive Officer

CERTIFICATIONS

I, Geert Kersten, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

	d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 12, 2023	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Financial Officer

EX-32 3 cvm_ex32.htm CERTIFICATION cvm_ex32.htm

EXHIBIT 32

In connection with the Quarterly Report of CEL-SCI Corporation (the “Company”) on Form 10-Q for the period ending March 31, 2023 as filed with the Securities and Exchange Commission (the “Report”), Geert Kersten, the Principal Executive and Principal Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.

	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive and
		Principal Financial Officer

May 12, 2023

EX-101.SCH 4 cvm-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - LIQUIDITY link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - PATENTS link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - STOCKHOLDERS EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - PATENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - STOCKHOLDERS EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - STOCKHOLDERS EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - STOCKHOLDERS EQUITY (Details 3) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - STOCKHOLDERS EQUITY (Details 4) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative ) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - PATENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - PATENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - LOSS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - LOSS PER COMMON SHARE (Details 1) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 cvm-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Interactive Data Current Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Document Quarterly Report Document Transition Report CONDENSED BALANCE SHEETS Current assets: Cash and cash equivalents Prepaid expenses Supplies used for R&D and manufacturing Deposits Total current assets [Assets, Current] Finance lease right of use assets Operating lease right of use assets Property and equipment, net Patent costs, net Deposits [Deposit Assets] Supplies used for R&D and manufacturing [Supplies used for R&D and manufacturing] Total assets [Assets] LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses Due to employees Lease liabilities, current portion Total current liabilities [Liabilities, Current] Finance lease obligations, net of current portion Operating lease obligations, net of current portion Other liabilities Total liabilities [Liabilities] Commitments and contingencies STOCKHOLDERS' EQUITY Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding Common stock, $.01 par value; 600,000,000 shares authorized; 43,787,825 and 43,448,317 shares issued and outstanding at March 31, 2023 and September 30, 2022, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY [Liabilities and Equity] Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) Operating expenses: Research and development General and administrative Total operating expenses [Operating Expenses] Operating loss [Operating Income (Loss)] Gain on derivative instruments Other non-operating losses Interest expense, net Other expense [Other Nonoperating Expense] Net loss [Net Income (Loss) Attributable to Parent] Modification of warrants Net loss available to common shareholders [Net Income (Loss) Available to Common Stockholders, Basic] Net loss per common share - basic and diluted Weighted average common shares outstanding - basic and diluted STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) Statement [Table] Statement [Line Items] Statement Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Balance, shares [Shares, Issued] Balance, amount Warrant exercises, shares Warrant exercises, amount Equity based compensation - employees 401(k) contributions paid in common stock, shares 401(k) contributions paid in common stock, amount Stock and options issued to nonemployees for service, share [Stock Issued During Period, Shares, Issued for Services] Stock and options issued to nonemployees for service, amount [Stock and options issued to nonemployees for service, amount] Option exercises, shares Option exercises, amount Share issuance costs Net loss Stock and options issued to nonemployees for service, shares Stock and options issued to nonemployees for service, amount [Stock Issued During Period, Value, Issued for Services] 2014 Incentive Stock Forfeited, shares 2014 Incentive Stock Forfeited, amount Stock and options issued to nonemployees for service, share Stock and options issued to nonemployees for service, amount Balance, shares Balance, amount CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) Net loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Non-cash lease expense Share-based payments for services Equity-based compensation Common stock contributed to 401(k) plan Gain on short-term investments [Gain (Loss) on Investments] Loss on patent impairment Gain on derivative instruments [Gain on derivative instruments] Loss on Receivables (Increase)/decrease in assets: Prepaid expenses [Increase (Decrease) in Prepaid Expense] Supplies used for R&D and manufacturing [Supplies used for R&D and manufacturing 1] Deposits [Deposits] Increase/(decrease) in liabilities: Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses [Increase (Decrease) in Accrued Liabilities] Due to employees [Increase (Decrease) in Employee Related Liabilities] Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from maturity of US treasury bills Purchases of property and equipment [Payments to Acquire Property, Plant, and Equipment] Expenditures for patent costs [Payments to Acquire Intangible Assets] Net cash (used in) provided by investing activities [Net Cash Provided by (Used in) Investing Activities] CASH FLOWS FROM FINANCING ACTIVITIES: Payments of stock issuance costs [Payments of Stock Issuance Costs] Proceeds from exercises of warrants Proceeds from the exercises of options Proceeds from landlord funding of lease improvements Payments on obligations under finance leases [Repayments of Debt and Lease Obligation] Net cash (used in) provided by financing activities [Net Cash Provided by (Used in) Financing Activities] NET DECREASE IN CASH AND CASH EQUIVALENTS [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect] CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] CASH AND CASH EQUIVALENTS, END OF PERIOD SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Property and equipment purchases included in current liabilities Finance lease obligation included in accounts payable Prepaid consulting services paid with issuance of common stock Exercise of derivative liabilities Modification of finance leases Financing costs included in current liabilities Accrued consulting services to be paid with common stock Cash paid for interest BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] LIQUIDITY LIQUIDITY [LIQUIDITY] STOCKHOLDERS EQUITY STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] PATENTS PATENTS Intangible Assets Disclosure [Text Block] EX-101.CAL 6 cvm-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 7 cvm-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 8 cvm-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	6 Months Ended
Cover - shares	Mar. 31, 2023	May 08, 2023
Cover [Abstract]
Entity Registrant Name	CEL-SCI CORPORATION
Entity Central Index Key	0000725363
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		44,714,679
Entity File Number	001-11889
Entity Incorporation State Country Code	CO
Entity Tax Identification Number	84-0916344
Entity Interactive Data Current	Yes
Entity Address Address Line 1	8229 Boone Boulevard
Entity Address Address Line 2	Suite 802
Entity Address City Or Town	Vienna
Entity Address State Or Province	VA
Entity Address Postal Zip Code	22182
City Area Code	703
Local Phone Number	506-9460
Security 12b Title	Common Stock
Trading Symbol	CVM
Security Exchange Name	NYSEAMER
Document Quarterly Report	true
Document Transition Report	false

XML 10 R2.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS - USD ($)	Mar. 31, 2023	Sep. 30, 2022
Current assets:
Cash and cash equivalents	$ 10,046,344	$ 22,672,138
Prepaid expenses	598,377	762,063
Supplies used for R&D and manufacturing	1,893,683	2,001,715
Deposits	35,622	0
Total current assets	12,574,026	25,435,916
Finance lease right of use assets	10,034,892	10,937,797
Operating lease right of use assets	1,793,399	1,884,464
Property and equipment, net	11,179,697	11,889,029
Patent costs, net	192,231	212,201
Deposits	2,319,101	0
Supplies used for R&D and manufacturing	101,897	164,299
Total assets	38,195,243	50,523,706
Current liabilities:
Accounts payable	1,888,911	1,618,290
Accrued expenses	1,064,007	842,492
Due to employees	509,286	471,488
Lease liabilities, current portion	1,849,749	1,731,481
Total current liabilities	5,311,953	4,663,751
Finance lease obligations, net of current portion	10,855,289	11,721,368
Operating lease obligations, net of current portion	1,755,401	1,850,380
Other liabilities	125,000	125,000
Total liabilities	18,047,643	18,360,499
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding	0	0
Common stock, $.01 par value; 600,000,000 shares authorized; 43,787,825 and 43,448,317 shares issued and outstanding at March 31, 2023 and September 30, 2022, respectively	437,878	434,484
Additional paid-in capital	490,803,133	486,625,816
Accumulated deficit	(471,093,411)	(454,897,093)
Total stockholders' equity	20,147,600	32,163,207
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 38,195,243	$ 50,523,706

XML 11 R3.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Sep. 30, 2022
CONDENSED BALANCE SHEETS
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	43,787,825	43,448,317
Common stock, shares outstanding	43,787,825	43,448,317
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	200,000	200,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML 12 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 6,083,488	$ 6,523,817	$ 11,476,034	$ 12,606,984
General and administrative	2,092,758	3,028,042	4,350,761	5,788,250
Total operating expenses	8,176,246	9,551,859	15,826,795	18,395,234
Operating loss	(8,176,246)	(9,551,859)	(15,826,795)	(18,395,234)
Gain on derivative instruments	0	2,195	0	366,791
Other non-operating losses			0	(30,793)
Interest expense, net	(159,063)	(273,828)	(311,852)	(546,862)
Other expense	(7,500)	0	(57,671)
Net loss	(8,342,809)	(9,823,492)	(16,196,318)	(18,606,098)
Modification of warrants			(171,552)	0
Net loss available to common shareholders	$ (8,342,809)	$ (9,823,492)	$ (16,367,870)	$ (18,606,098)
Net loss per common share - basic and diluted	$ (0.19)	$ (0.23)	$ (0.38)	$ (0.43)
Weighted average common shares outstanding - basic and diluted	43,588,381	43,122,671	43,513,571	43,100,070

XML 13 R5.htm IDEA: XBRL DOCUMENT

STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Sep. 30, 2021		43,207,183
Balance, amount at Sep. 30, 2021	$ 56,534,226	$ 432,072	$ 474,298,566	$ (418,196,412)
Warrant exercises, shares		19,705
Warrant exercises, amount	157,954	$ 197	157,757
Equity based compensation - employees	3,262,296		3,262,296
401(k) contributions paid in common stock, shares		7,605
401(k) contributions paid in common stock, amount	52,555	$ 76	52,479
Stock and options issued to nonemployees for service, share		18,020
Stock and options issued to nonemployees for service, amount	143,160	$ 180	142,980
Option exercises, shares		6,500
Option exercises, amount	29,835	$ 65	29,770
Share issuance costs	(45,965)		(45,965)
Net loss	(8,782,606)			(8,782,606)
Balance, shares at Dec. 31, 2021		43,259,013
Balance, amount at Dec. 31, 2021	51,351,455	$ 432,590	477,897,883	(426,979,018)
Balance, shares at Sep. 30, 2021		43,207,183
Balance, amount at Sep. 30, 2021	56,534,226	$ 432,072	474,298,566	(418,196,412)
Net loss	(18,606,098)
Balance, shares at Mar. 31, 2022		43,304,602
Balance, amount at Mar. 31, 2022	45,127,548	$ 433,046	481,497,012	(436,802,510)
Balance, shares at Dec. 31, 2021		43,259,013
Balance, amount at Dec. 31, 2021	51,351,455	$ 432,590	477,897,883	(426,979,018)
Warrant exercises, shares		5,500
Warrant exercises, amount	13,860	$ 55	13,805
Equity based compensation - employees	3,392,706		3,392,706
401(k) contributions paid in common stock, shares		14,614
401(k) contributions paid in common stock, amount	$ 57,517	$ 146	57,371
Stock and options issued to nonemployees for service, share	25,475
Share issuance costs	$ (4,550)		(4,550)
Net loss	(9,823,492)			(9,823,492)
Stock and options issued to nonemployees for service, shares		25,475
Stock and options issued to nonemployees for service, amount	140,052	$ 255	139,797
Stock and options issued to nonemployees for service, amount	(140,052)	$ (255)	(139,797)
Balance, shares at Mar. 31, 2022		43,304,602
Balance, amount at Mar. 31, 2022	45,127,548	$ 433,046	481,497,012	(436,802,510)
Balance, shares at Sep. 30, 2022		43,448,317
Balance, amount at Sep. 30, 2022	32,163,207	$ 434,484	486,625,816	(454,897,093)
Warrant exercises, shares		217,752
Warrant exercises, amount	447,291	$ 2,177	445,114
Equity based compensation - employees	1,703,931		1,703,931
401(k) contributions paid in common stock, shares		21,331
401(k) contributions paid in common stock, amount	50,178	$ 213	49,965
Net loss	(7,853,509)			(7,853,509)
Stock and options issued to nonemployees for service, shares		40,236
Stock and options issued to nonemployees for service, amount	91,623	$ 402	91,221
2014 Incentive Stock Forfeited, shares		(2,000)
2014 Incentive Stock Forfeited, amount	(11,100)	$ (20)	(11,080)
Stock and options issued to nonemployees for service, amount	(91,623)	$ (402)	(91,221)
Balance, shares at Dec. 31, 2022		43,725,636
Balance, amount at Dec. 31, 2022	26,591,621	$ 437,256	488,904,967	(462,750,602)
Balance, shares at Sep. 30, 2022		43,448,317
Balance, amount at Sep. 30, 2022	32,163,207	$ 434,484	486,625,816	(454,897,093)
Net loss	(16,196,318)
Balance, shares at Mar. 31, 2023		43,787,825
Balance, amount at Mar. 31, 2023	20,147,600	$ 437,878	490,803,133	(471,093,411)
Balance, shares at Dec. 31, 2022		43,725,636
Balance, amount at Dec. 31, 2022	26,591,621	$ 437,256	488,904,967	(462,750,602)
Equity based compensation - employees	1,743,288		1,743,288
401(k) contributions paid in common stock, shares		23,627
401(k) contributions paid in common stock, amount	$ 54,865	$ 236	$ 54,629
Stock and options issued to nonemployees for service, share	38,562
Net loss	$ (8,342,809)
Stock and options issued to nonemployees for service, amount	$ 8,342,809			$ 8,342,809
Stock and options issued to nonemployees for service, share	100,635	38,562	386	100,249
Stock and options issued to nonemployees for service, amount	$ (8,342,809)			$ (8,342,809)
Balance, shares at Mar. 31, 2023		43,787,825
Balance, amount at Mar. 31, 2023	$ 20,147,600	$ 437,878	$ 490,803,133	$ (471,093,411)

XML 14 R6.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)
Net loss	$ (16,196,318)	$ (18,606,098)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,973,982	1,867,192
Non-cash lease expense	9,545	43,594
Share-based payments for services	285,722	402,270
Equity-based compensation	3,436,119	6,655,002
Common stock contributed to 401(k) plan	105,043	110,072
Gain on short-term investments	0	(615)
Loss on patent impairment	0	30,793
Gain on derivative instruments	0	(366,791)
Loss on Receivables	0	54,922
(Increase)/decrease in assets:
Prepaid expenses	180,222	2,552
Supplies used for R&D and manufacturing	170,434	1,288
Deposits	(2,354,723)	1,910,917
Increase/(decrease) in liabilities:
Accounts payable	102,841	46,033
Accrued expenses	111,515	89,149
Due to employees	37,798	222,112
Net cash used in operating activities	(12,137,820)	(7,537,608)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from maturity of US treasury bills	0	6,152,000
Purchases of property and equipment	(165,032)	(550,861)
Expenditures for patent costs	0	(22,741)
Net cash (used in) provided by investing activities	(165,032)	5,578,398
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of stock issuance costs	(9,010)	(45,965)
Proceeds from exercises of warrants	447,291	101,225
Proceeds from the exercises of options	0	29,835
Proceeds from landlord funding of lease improvements	0	786,454
Payments on obligations under finance leases	(761,223)	(689,615)
Net cash (used in) provided by financing activities	(322,942)	181,934
NET DECREASE IN CASH AND CASH EQUIVALENTS	(12,625,794)	(1,777,276)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	22,672,138	36,060,148
CASH AND CASH EQUIVALENTS, END OF PERIOD		34,282,872
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment purchases included in current liabilities	176,743	32,549
Finance lease obligation included in accounts payable	1,402	374
Prepaid consulting services paid with issuance of common stock	192,258	354,853
Exercise of derivative liabilities	0	70,589
Modification of finance leases	0	16,268
Financing costs included in current liabilities	0	4,550
Accrued consulting services to be paid with common stock	165,000	165,000
Cash paid for interest	$ 547,765	$ 578,837

XML 15 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Mar. 31, 2023

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Summary of Significant Accounting Policies:

XML 16 R8.htm IDEA: XBRL DOCUMENT

LIQUIDITY

6 Months Ended

Mar. 31, 2023

LIQUIDITY

LIQUIDITY

B. LIQUIDITY

XML 17 R9.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY

6 Months Ended

Mar. 31, 2023

STOCKHOLDERS EQUITY

STOCKHOLDERS' EQUITY

C. STOCKHOLDERS’ EQUITY

Equity Compensation

Underlying share information for equity compensation plans as of March 31, 2023 is as follows:

Name of Plan	Total Shares Reserved Under Plans

Incentive Stock Option Plans		138,400
Non-Qualified Stock Option Plans		13,787,200
Stock Bonus Plans		783,760
Stock Compensation Plans		634,000
Incentive Stock Bonus Plan		640,000

Stock option activity:

	Six Months Ended March 31,
	2023		2022
Options granted		4,500		252,500
Options exercised		-		6,500
Options forfeited		122,332		20,166
Options expired		45,404		-

	Three Months Ended March 31,
	2023		2022
Options granted		2,000		1,500
Options exercised		-		-
Options forfeited		25,500		7,166
Options expired		4		-

Stock-Based Compensation Expense

	Six months Ended March 31,
	2023		2022
Employees	$	3,436,119	$	6,655,002
Non-employees	$	285,722	$	402,270

	Three months Ended March 31,
	2023		2022
Employees	$	1,743,288	$	3,392,706
Non-employees	$	136,864	$	183,952

Warrants and Non-Employee Options

The following chart represents the warrants and non-employee options outstanding at March 31, 2023:

Warrant/ Options	Issue Date	Shares Issuable upon Exercise of Warrants/ Options	Exercise Price	Expiration Date	Reference
Series N	8/18/2008	85,339	$3.00	8/18/2024	*
Series UU	6/11/2018	93,603	$2.80	6/30/2024	*
Series X	1/13/2016	120,000	$9.25	7/13/2024	*
Series Y	2/15/2016	26,000	$12.00	8/15/2024	*
Series MM	6/22/2017	333,432	$1.86	6/22/2024	*
Series NN	7/24/2017	200,087	$2.52	7/24/2024	*
Series RR	10/30/2017	234,009	$1.65	10/30/2024	*
Series TT	2/5/2018	-	$2.24	2/5/2023	2
Consultant Options	7/28/2017	10,000	$2.18	7/27/2027	*

* No current period changes for these warrants

1. Derivative Liabilities

The table below presents the gains on the warrant liabilities for the six months ended March 31:

	2023		2022
Series Z warrants	$	-	$	64,787
Series AA warrants		-		274,635
Series CC warrants		-		24,372
Series HH warrants		-		1,597
Net gain on warrant liabilities	$	-	$	366,791

The table below presents the gains on the warrant liabilities for the three months ended March 31:

	2023		2022
Series AA warrants	$	-	$	1,400
Series HH warrants		-		795
Net gain on warrant liabilities	$	-	$	2,195

Changes in Warrant Liabilities

As of March 31, 2023, no warrant liabilities were outstanding.

2. Equity Warrants

Changes in Equity Warrants

On February 5, 2023, 600 Series TT warrants, with an exercise price of $2.24, expired.

3. Options and Shares Issued to Consultants

During the six months ended March 31, 2023, 5,000 options with an exercise price of $11.61 issued to a consultant expired.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 18 R10.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS

6 Months Ended

Mar. 31, 2023

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

D. FAIR VALUE MEASUREMENTS

	●	Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities

	●	Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets

	●	Level 3 – Unobservable inputs that reflect management’s assumptions. Assumptions from market participants are used when pricing the asset or liabilities, given there is no readily available market information.

	Six months ended March 31, 2023		Six months ended March 31, 2022

Beginning balance	$	-	$	437,380
Issuances		-		-
Exercises		-		(70,589	)
Realized and unrealized (gains) and losses		-		(366,791	)
Ending balance	$	-	$	-

	Three months ended March 31, 2023		Three months ended March 31, 2022

Beginning balance	$	-	$	2,195
Issuances		-		-
Exercises		-
Realized and unrealized (gains) and losses		-		(2,195	)
Ending balance	$	-	$	-

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 19 R11.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

6 Months Ended

Mar. 31, 2023

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

E. RELATED PARTY TRANSACTIONS

XML 20 R12.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Mar. 31, 2023

Commitments and contingencies

COMMITMENTS AND CONTINGENCIES

F. COMMITMENTS AND CONTINGENCIES

Clinical Research Agreement

Lease Agreements

Approximate future minimum lease payments under finance leases as of March 31, 2023 are as follows:

Six months ending September 30, 2023	$	1,291,000
Year ending September 30,
2024		2,655,000
2025		2,741,000
2026		2,832,000
2027		2,923,000
2028		3,015,000
Thereafter		252,000
Total future minimum lease obligation		15,709,000
Less imputed interest on finance lease obligations		(3,189,000	)
Net present value of finance lease obligations	$	12,520,000

As of March 31, 2023, future minimum lease payments on operating leases are as follows:

Six months ending September 30, 2023	$	176,000
Year ending September 30,
2024		357,000
2025		366,000
2026		287,000
2027		277,000
2028		285,000
Thereafter		1,040,000
Total future minimum lease obligation		2,788,000
Less imputed interest on operating lease obligation		(849,000	)
Net present value of operating lease obligation	$	1,939,000

XML 21 R13.htm IDEA: XBRL DOCUMENT

PATENTS

6 Months Ended

Mar. 31, 2023

PATENTS

PATENTS

G. PATENTS

Six months ending September 30, 2023	$	18,000
Year ending September 30,
2024		30,000
2025		28,000
2026		24,000
2027		21,000
2028		17,000
Thereafter		54,000
Total	$	192,000

XML 22 R14.htm IDEA: XBRL DOCUMENT

LOSS PER COMMON SHARE

6 Months Ended

Mar. 31, 2023

LOSS PER COMMON SHARE

LOSS PER COMMON SHARE

H. LOSS PER COMMON SHARE

Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period.

The following tables provide the details of the basic and diluted loss per-share computations:

	Six months ended March 31,						Three months ended March 31,
	2023			2022			2023			2022
Loss per share – basic and diluted
Net loss available to common shareholders – basic and diluted	$	(16,367,869	)	$	(18,606,098	)	$	(8,342,809	)	$	(9,823,492	)
Weighted average shares outstanding – basic and diluted		43,513,571			43,100,070			43,588,381			43,122,671
Basic and diluted loss per common share	$	(0.38	)	$	(0.43	)	$	(0.19	)	$	(0.23	)

	2023		2022

Options and Warrants		13,893,248		12,586,365
Unvested Restricted Stock		149,250		151,250
Total		14,042,498		12,737,615

XML 23 R15.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

6 Months Ended

Mar. 31, 2023

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

J. SUBSEQUENT EVENTS

XML 24 R16.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Mar. 31, 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Cash and Cash Equivalents	Cash and Cash Equivalents – Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash and cash equivalents.
U S Treasury Bills	U.S. Treasury Bills – U.S. Treasury Bills (“T-bills”) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.
Property and Equipment	Property and Equipment – Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.
Supplies used for R&D and manufacturing	Supplies used for R&D and manufacturing – Supplies are consumable items kept on hand to support the Company’s R&D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.
Patents	Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.
Leases	Leases – The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.
Derivative Instruments	Derivative Instruments – The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, Accounting for Derivative Instruments and Hedging Activities. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period. The Company adopted Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in an Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity effective October 1, 2021. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. There was no financial impact in the period of adoption.
Stock-Based Compensation	Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, Compensation – Stock Compensation. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period. The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company’s stockholders. The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period. Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.
Research and Development Costs	Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.
Net Loss Per Common Share	Net Loss Per Common Share – The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.
Income Taxes	Income Taxes – The Company accounts for income taxes in accordance with the provisions of ASC 740, "Income Taxes" ("ASC 740"), on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of March 31, 2023 and September 30, 2022. The Company adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company’s financial statements.
Use of Estimates	Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes option pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.
New Accounting Pronouncements	New Accounting Pronouncements - The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

XML 25 R17.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Tables)

6 Months Ended

Mar. 31, 2023

STOCKHOLDERS EQUITY

Schedule of equity compensation plans

Name of Plan	Total Shares Reserved Under Plans

Incentive Stock Option Plans		138,400
Non-Qualified Stock Option Plans		13,787,200
Stock Bonus Plans		783,760
Stock Compensation Plans		634,000
Incentive Stock Bonus Plan		640,000

Schedule of Stock option activity

	Six Months Ended March 31,
	2023		2022
Options granted		4,500		252,500
Options exercised		-		6,500
Options forfeited		122,332		20,166
Options expired		45,404		-

	Three Months Ended March 31,
	2023		2022
Options granted		2,000		1,500
Options exercised		-		-
Options forfeited		25,500		7,166
Options expired		4		-

Schedule of Stock-Based Compensation Expense

	Six months Ended March 31,
	2023		2022
Employees	$	3,436,119	$	6,655,002
Non-employees	$	285,722	$	402,270

	Three months Ended March 31,
	2023		2022
Employees	$	1,743,288	$	3,392,706
Non-employees	$	136,864	$	183,952

Schedule of warrants and non-employee options outstanding

Warrant/ Options	Issue Date	Shares Issuable upon Exercise of Warrants/ Options	Exercise Price	Expiration Date	Reference
Series N	8/18/2008	85,339	$3.00	8/18/2024	*
Series UU	6/11/2018	93,603	$2.80	6/30/2024	*
Series X	1/13/2016	120,000	$9.25	7/13/2024	*
Series Y	2/15/2016	26,000	$12.00	8/15/2024	*
Series MM	6/22/2017	333,432	$1.86	6/22/2024	*
Series NN	7/24/2017	200,087	$2.52	7/24/2024	*
Series RR	10/30/2017	234,009	$1.65	10/30/2024	*
Series TT	2/5/2018	-	$2.24	2/5/2023	2
Consultant Options	7/28/2017	10,000	$2.18	7/27/2027	*

Schedule of derivative liabilities

	2023		2022
Series Z warrants	$	-	$	64,787
Series AA warrants		-		274,635
Series CC warrants		-		24,372
Series HH warrants		-		1,597
Net gain on warrant liabilities	$	-	$	366,791

	2023		2022
Series AA warrants	$	-	$	1,400
Series HH warrants		-		795
Net gain on warrant liabilities	$	-	$	2,195

XML 26 R18.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Tables)

6 Months Ended

Mar. 31, 2023

FAIR VALUE MEASUREMENTS

Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)

	Six months ended March 31, 2023		Six months ended March 31, 2022

Beginning balance	$	-	$	437,380
Issuances		-		-
Exercises		-		(70,589	)
Realized and unrealized (gains) and losses		-		(366,791	)
Ending balance	$	-	$	-

	Three months ended March 31, 2023		Three months ended March 31, 2022

Beginning balance	$	-	$	2,195
Issuances		-		-
Exercises		-
Realized and unrealized (gains) and losses		-		(2,195	)
Ending balance	$	-	$	-

XML 27 R19.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Tables)

6 Months Ended

Mar. 31, 2023

Commitments and contingencies

Schedule of future minimum payments under finance leases

Six months ending September 30, 2023	$	1,291,000
Year ending September 30,
2024		2,655,000
2025		2,741,000
2026		2,832,000
2027		2,923,000
2028		3,015,000
Thereafter		252,000
Total future minimum lease obligation		15,709,000
Less imputed interest on finance lease obligations		(3,189,000	)
Net present value of finance lease obligations	$	12,520,000

Schedule of future minimum payments under operating leases

Six months ending September 30, 2023	$	176,000
Year ending September 30,
2024		357,000
2025		366,000
2026		287,000
2027		277,000
2028		285,000
Thereafter		1,040,000
Total future minimum lease obligation		2,788,000
Less imputed interest on operating lease obligation		(849,000	)
Net present value of operating lease obligation	$	1,939,000

XML 28 R20.htm IDEA: XBRL DOCUMENT

PATENTS (Tables)

6 Months Ended

Mar. 31, 2023

PATENTS

Schedule of total estimated future amortization

Six months ending September 30, 2023	$	18,000
Year ending September 30,
2024		30,000
2025		28,000
2026		24,000
2027		21,000
2028		17,000
Thereafter		54,000
Total	$	192,000

XML 29 R21.htm IDEA: XBRL DOCUMENT

LOSS PER COMMON SHARE (Tables)

6 Months Ended

Mar. 31, 2023

LOSS PER COMMON SHARE

Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations

	Six months ended March 31,						Three months ended March 31,
	2023			2022			2023			2022
Loss per share – basic and diluted
Net loss available to common shareholders – basic and diluted	$	(16,367,869	)	$	(18,606,098	)	$	(8,342,809	)	$	(9,823,492	)
Weighted average shares outstanding – basic and diluted		43,513,571			43,100,070			43,588,381			43,122,671
Basic and diluted loss per common share	$	(0.38	)	$	(0.43	)	$	(0.19	)	$	(0.23	)

Schedule of anti-dilutive securities

	2023		2022

Options and Warrants		13,893,248		12,586,365
Unvested Restricted Stock		149,250		151,250
Total		14,042,498		12,737,615

XML 30 R22.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Details)	Dec. 31, 2023 shares
Remaining Options/shares Under Plans	138,400
Non-Qualified Stock Option Plans [Member]
Remaining Options/shares Under Plans	13,787,200
Stock Bonus Plans [Member]
Remaining Options/shares Under Plans	783,760
Stock Compensation Plan [Member]
Remaining Options/shares Under Plans	634,000
Incentive Stock Bonus Plan [Member]
Remaining Options/shares Under Plans	640,000

XML 31 R23.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Details 1) - shares	3 Months Ended		6 Months Ended
STOCKHOLDERS EQUITY (Details 1) - shares	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
STOCKHOLDERS EQUITY
Options Granted	2,000	1,500	4,500	252,500
Options Exercised				6,500
Options Forfeited	25,500	7,166	122,332	20,166
Options Expired	4		45,404

XML 32 R24.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Details 2) - USD ($)	3 Months Ended		6 Months Ended
STOCKHOLDERS EQUITY (Details 2) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
STOCKHOLDERS EQUITY
Employees Stock Based Compensation Expense	$ 1,743,288	$ 3,392,706	$ 3,436,119	$ 6,655,002
Non- Employees Stock Based Compensation Expense	$ 136,864	$ 183,952	$ 285,722	$ 402,270

XML 33 R25.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Details 3) - $ / shares	6 Months Ended
STOCKHOLDERS EQUITY (Details 3) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Consultants Options [Member]
Issue Date	7/28/2017
Shares Issuable Upon Exercise Of Warrant/options		10,000
Exercise Price		$ 2.18
Expiration Date	7/27/2027
Series N [Member]
Issue Date	8/18/2008
Shares Issuable Upon Exercise Of Warrant/options		85,339
Exercise Price		$ 3.00
Expiration Date	8/18/2024
Series UU [Member]
Issue Date	6/11/2018
Shares Issuable Upon Exercise Of Warrant/options		93,603
Exercise Price		$ 2.80
Expiration Date	6/30/2024
Series X [Member]
Issue Date	1/13/2016
Shares Issuable Upon Exercise Of Warrant/options		120,000
Exercise Price		$ 9.25
Expiration Date	7/13/2024
Series Y [Member]
Issue Date	2/15/2016
Shares Issuable Upon Exercise Of Warrant/options		26,000
Exercise Price		$ 12.00
Expiration Date	8/15/2024
Series MM [Member]
Issue Date	6/22/2017
Shares Issuable Upon Exercise Of Warrant/options		333,432
Exercise Price		$ 1.86
Expiration Date	6/22/2024
Series NN [Member]
Issue Date	7/24/2017
Shares Issuable Upon Exercise Of Warrant/options		200,087
Exercise Price		$ 2.52
Expiration Date	7/24/2024
Series RR [Member]
Issue Date	10/30/2017
Shares Issuable Upon Exercise Of Warrant/options		234,009
Exercise Price		$ 1.65
Expiration Date	10/30/2024
Series TT [Member]
Issue Date	2/5/2018
Exercise Price		$ 2.24
Expiration Date	2/5/2023

XML 34 R26.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Details 4) - USD ($)	3 Months Ended		6 Months Ended
STOCKHOLDERS EQUITY (Details 4) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Series Z Warrants	$ 0	$ 64,787	$ 0	$ 64,787
Series AA Warrants	0	274,635	0	274,635
Series CC Warrants	0	24,372	0	24,372
Series HH Warrants	0	1,597	0	1,597
Net Gain On Warrant Liabilities	0	2,195	0	366,791
Derivative Liabilities
Series AA Warrants	0	1,400	0	1,400
Series HH Warrants	$ 0	$ 795	$ 0	$ 795

XML 35 R27.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)		1 Months Ended			3 Months Ended			6 Months Ended
STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	Feb. 05, 2023	Feb. 28, 2022	Dec. 31, 2021	Nov. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022
Incremental cost								$ 172,000
Weighted average grant date fair value					$ 2.42	$ 5.00
Common stock issued for service, shares					38,562	25,475
Series AA [Member]
Warrants exercised		100,000
Exercise price per share		$ 13.75
Consulting Agreements [Member]
Total expense								285,000	$ 402,000
Consulting fees inclued prepaid expenses			$ 295,000		$ 311,000		$ 295,000	$ 311,000
Consultants [Member]
Exercise price								$ 11.61
Options issued								5,000
Consultants [Member] \| Restricted Stock [Member]
Weighted average grant date fair value							$ 7.05	$ 2.47
Common stock issued for service, shares							43,495	78,798
Series NN [Member]
Warrants exercised						5,500		10,000
Proceeds from warrants exercised						$ 13,860		$ 25,200
Exercise Price						$ 2.52		$ 2.52
Series RR [Member]
Warrants exercised								17,752
Exercise Price								$ 1.65
Series TT [Member]
Warrants exercised	600
Exercise Price	$ 2.24
Series SS [Member]
Warrants exercised								200,000
Proceeds from warrants exercised								$ 447,291
Exercise Price								$ 2.09
Series CC [Member]
Warrants exercised			640						15,205
Proceeds from warrants exercised									$ 76,025
Exercise price per share			$ 5.00						$ 5.00
Series Z [Member]
Warrants exercised				184,800
Exercise Price				$ 13.75
Series HH [Member]
Warrants exercised		200
Non-Qualified Stock Option Plans [Member]
Grant performance-based stock options							250,000
Common stock price			$ 10.48				$ 10.48
Stock options vest			100.00%				100.00%

XML 36 R28.htm IDEA: XBRL DOCUMENT

FAIR VALUE MEASUREMENTS (Details) - USD ($)	3 Months Ended		6 Months Ended
FAIR VALUE MEASUREMENTS (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
FAIR VALUE MEASUREMENTS
Beginning Balance	$ 0	$ 2,195	$ 0	$ 437,380
Issuances	0	0	0	0
Exercises	0	0	0	(70,589)
Realized And Unrealized (gains) And Losses	0	(2,195)	0	(366,791)
Ending Balance	$ 0	$ 0	$ 0	$ 0

XML 37 R29.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative )	1 Months Ended
RELATED PARTY TRANSACTIONS (Details Narrative )	Oct. 28, 2022 USD ($)
CEO, Geert Kersten [Member]
Modifications cost	$ 172,552

XML 38 R30.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details)	Mar. 31, 2023 USD ($)
Commitments and contingencies
Six months ending September 30, 2023	$ 1,291,000
2024	2,655,000
2025	2,741,000
2026	2,832,000
2027	2,923,000
2028	3,015,000
Thereafter	252,000
Total Future Minimum Lease Obligation	15,709,000
Less: Imputed Interest On Financing Lease Obligation	(3,189,000)
Net Present Value Of Finance Lease Obligations	$ 12,520,000

XML 39 R31.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details 1)	Dec. 31, 2023 USD ($)
Commitments and contingencies
Six months ending September 30, 2023	$ 176,000
2024	357,000
2025	366,000
2026	287,000
2027	277,000
2028	285,000
Thereafter	1,040,000
Total Future Minimum Lease Obligation	2,788,000
Less Imputed Interest On Operating Lease Obligation	(849,000)
Net Present Value Of Operating Lease Obligation	$ 1,939,000

XML 40 R32.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Sep. 30, 2022
Net Of Discount			$ 1,180,000
Research And Development Expenses			3,560,000
Increase In Right Of Use Asset And Liability			110,000
Operating Lease Right Of Use Assets	$ 180,000		180,000		$ 190,000
Operating Lease Liabilities	$ 190,000		$ 190,000		200,000.0
Weighted Average Discount Rate Operating Lease	10.20%		10.20%
Current portion of the operating lease obligation	$ 20,000		$ 20,000
Current Balance	$ 200,000		200,000
Operating Lease Expense			100,000	$ 200,000
Operating Lease Payment			$ 200,000	100,000
Weighted Average Time To Maturity			8 years 1 month 20 days
Landlord [Member]
Interest Rate	8.40%		8.40%
Financing arrangement deposit base rent amount			$ 230,000
Financing arrangement deposit base rent percentage description			The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year
Financing Arrangement			$ 1,110,000
Payments Made By Landlord			$ 240,000
Transaction One [Member]
Weighted average maturity date of operating leases			5 years 7 months 6 days
Weighted Average Discount Rate	8.45%		8.45%
Net Book Value Of The Finance Lease Right Of Use Asset	$ 1,000,000.0		$ 1,000,000.0		109,000
Balance Of The Finance Lease Liability	1,250,000		1,250,000		$ 1,330,000
Cash Paid Related To Finance Leases			1,300,000	1,300,000.0
Cash Paid Related To Finance Leases Interest			60,000
Ergomed [Member]
Research And Development Expenses	$ 0.0	$ 2,000	100,000	$ 4,000
Clinical Service Trial			$ 12,000,000

XML 41 R33.htm IDEA: XBRL DOCUMENT

PATENTS (Details)	Mar. 31, 2023 USD ($)
PATENTS
Six months ending September 30, 2023	$ 18,000
2024	30,000
2025	28,000
2026	24,000
2027	21,000
2028	17,000
Thereafter	54,000
Total	$ 192,000

XML 42 R34.htm IDEA: XBRL DOCUMENT

PATENTS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
PATENTS (Details Narrative) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
PATENTS
Patent Impairment Charges			$ 0	$ 31,000
Amortization Of Patent Costs	$ 10,000	$ 13,000	$ 20,000	$ 27,000

XML 43 R35.htm IDEA: XBRL DOCUMENT

LOSS PER COMMON SHARE (Details) - USD ($)	3 Months Ended		6 Months Ended
LOSS PER COMMON SHARE (Details) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Loss per share- basic and diluted
Net loss available to common shareholders - basic and diluted	$ (8,342,809)	$ (9,823,492)	$ (16,367,869)	$ (18,606,098)
Weighted average shares outstanding - basic and diluted	43,588,381	43,122,671	43,513,571	43,100,070
Basic and diluted loss per common share	$ (0.19)	$ (0.23)	$ (0.38)	$ (0.43)

XML 44 R36.htm IDEA: XBRL DOCUMENT

LOSS PER COMMON SHARE (Details 1) - shares	6 Months Ended
LOSS PER COMMON SHARE (Details 1) - shares	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities	14,042,498	12,737,615
Options and Warrants
Antidilutive Securities	13,893,248	12,586,365
Unvested Restricted Stock [Member]
Antidilutive Securities	149,250	151,250

XML 45 R37.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event - USD ($)	1 Months Ended
	May 02, 2023	Apr. 27, 2023
Common stock sold		794,117
Public offering price		$ 1.70
Net proceed		$ 1,100,000
Additional shares of common stock		119,117
Additional Net Proceed	$ 190,000

XML 46 cvm_10q_htm.xml IDEA: XBRL DOCUMENT 0000725363 2022-10-01 2023-03-31 0000725363 us-gaap:SubsequentEventMember 2023-04-01 2023-05-02 0000725363 us-gaap:SubsequentEventMember 2023-04-01 2023-04-27 0000725363 cvm:UnvestedRestrictedStockMember 2021-10-01 2022-03-31 0000725363 cvm:UnvestedRestrictedStockMember 2022-10-01 2023-03-31 0000725363 cvm:OptionsMember 2021-10-01 2022-03-31 0000725363 cvm:OptionsMember 2022-10-01 2023-03-31 0000725363 2021-09-30 2022-03-31 0000725363 cvm:LandlordMember 2022-10-01 2023-03-31 0000725363 cvm:LandlordMember 2023-03-31 0000725363 cvm:TransactionOneMember 2021-10-01 2022-03-31 0000725363 cvm:TransactionOneMember 2022-09-30 0000725363 cvm:TransactionOneMember 2023-03-31 0000725363 cvm:TransactionOneMember 2022-10-01 2023-03-31 0000725363 cvm:ErgomedMember 2021-10-01 2022-03-31 0000725363 cvm:ErgomedMember 2022-01-01 2022-03-31 0000725363 cvm:ErgomedMember 2023-01-01 2023-03-31 0000725363 cvm:ErgomedMember 2022-10-01 2023-03-31 0000725363 cvm:CEOGeertKerstenMember 2022-10-01 2022-10-28 0000725363 cvm:ConsultingAgreementsMember 2021-12-31 0000725363 cvm:ConsultingAgreementsMember 2023-03-31 0000725363 cvm:ConsultingAgreementsMember 2022-10-01 2023-03-31 0000725363 cvm:ConsultingAgreementsMember 2021-10-01 2022-03-31 0000725363 cvm:NonQualifiedStockOptionsPlansMember 2021-12-31 0000725363 cvm:NonQualifiedStockOptionsPlansMember 2021-10-01 2021-12-31 0000725363 cvm:ConsultantsMember 2022-10-01 2023-03-31 0000725363 cvm:RestrictedStocksMember cvm:ConsultantsMember 2021-10-01 2021-12-31 0000725363 cvm:RestrictedStocksMember cvm:ConsultantsMember 2022-10-01 2023-03-31 0000725363 cvm:SeriesZMember 2021-11-01 2021-11-30 0000725363 cvm:SeriesSSMember 2022-10-01 2023-03-31 0000725363 cvm:SeriesNNMember 2022-01-01 2022-03-31 0000725363 cvm:SeriesCcMember 2021-12-01 2021-12-31 0000725363 cvm:SeriesTTMember 2023-02-01 2023-02-05 0000725363 cvm:SeriesHHMember 2022-02-01 2022-02-28 0000725363 cvm:SeriesCcMember 2021-10-01 2022-03-31 0000725363 cvm:SeriesAAMember 2022-02-01 2022-02-28 0000725363 cvm:DerivativeLiabilitiesMember 2022-03-31 0000725363 cvm:DerivativeLiabilitiesMember 2023-03-31 0000725363 cvm:ConsultantsOptionMember 2022-12-31 0000725363 cvm:ConsultantsOptionMember 2022-10-01 2023-03-31 0000725363 cvm:SeriesTTMember 2022-12-31 0000725363 cvm:SeriesTTMember 2022-10-01 2023-03-31 0000725363 cvm:SeriesRRMember 2022-12-31 0000725363 cvm:SeriesRRMember 2022-10-01 2023-03-31 0000725363 cvm:SeriesNNMember 2022-12-31 0000725363 cvm:SeriesNNMember 2022-10-01 2023-03-31 0000725363 cvm:SeriesMMMember 2022-12-31 0000725363 cvm:SeriesMMMember 2022-10-01 2023-03-31 0000725363 cvm:SeriesYMember 2022-12-31 0000725363 cvm:SeriesYMember 2022-10-01 2023-03-31 0000725363 cvm:SeriesXMember 2022-12-31 0000725363 cvm:SeriesXMember 2022-10-01 2023-03-31 0000725363 cvm:SeriesUUMember 2022-12-31 0000725363 cvm:SeriesUUMember 2022-10-01 2023-03-31 0000725363 cvm:SeriesNMember 2022-12-31 0000725363 cvm:SeriesNMember 2022-10-01 2023-03-31 0000725363 us-gaap:StockCompensationPlanMember 2023-12-31 0000725363 cvm:StockBonusPlansMember 2023-12-31 0000725363 cvm:NonQualifiedStockOptionsPlansMember 2023-12-31 0000725363 cvm:IncentiveStockBonusPlansMember 2023-12-31 0000725363 2023-12-31 0000725363 us-gaap:RetainedEarningsMember 2023-03-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000725363 us-gaap:CommonStockMember 2023-03-31 0000725363 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000725363 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000725363 2022-12-31 0000725363 us-gaap:RetainedEarningsMember 2022-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000725363 us-gaap:CommonStockMember 2022-12-31 0000725363 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0000725363 2022-10-01 2022-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0000725363 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0000725363 us-gaap:RetainedEarningsMember 2022-09-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000725363 us-gaap:CommonStockMember 2022-09-30 0000725363 2022-03-31 0000725363 us-gaap:RetainedEarningsMember 2022-03-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000725363 us-gaap:CommonStockMember 2022-03-31 0000725363 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000725363 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000725363 2021-12-31 0000725363 us-gaap:RetainedEarningsMember 2021-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000725363 us-gaap:CommonStockMember 2021-12-31 0000725363 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0000725363 2021-10-01 2021-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0000725363 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0000725363 2021-09-30 0000725363 us-gaap:RetainedEarningsMember 2021-09-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000725363 us-gaap:CommonStockMember 2021-09-30 0000725363 2021-10-01 2022-03-31 0000725363 2023-01-01 2023-03-31 0000725363 2022-01-01 2022-03-31 0000725363 2022-09-30 0000725363 2023-03-31 0000725363 2023-05-08 iso4217:USD shares iso4217:USD shares pure 0000725363 false --09-30 Q2 2023

0.01

600000000

43448317

43787825

0.01

200000

200000 1300000.0 10-Q true 2023-03-31 false 001-11889 CEL-SCI CORPORATION CO 84-0916344 8229 Boone Boulevard Suite 802 Vienna VA 22182 703 506-9460 Common Stock CVM NYSEAMER Yes Yes Non-accelerated Filer true false false 44714679

10046344

22672138

598377

762063

1893683 2001715 35622 0

12574026

25435916

10034892

10937797

1793399

1884464

11179697

11889029

192231

212201

2319101

101897 164299

38195243

50523706

1888911

1618290

1064007

842492

509286

471488

1849749 1731481

5311953

4663751

10855289

11721368

1755401

1850380

125000

18047643

18360499

0.01

200000

0.01

600000000

43787825

43448317

437878

434484

490803133

486625816

-471093411

-454897093

20147600

32163207

38195243

50523706

11476034

12606984

4350761

5788250

15826795

18395234

-15826795

-18395234

366791

-30793

-311852

-546862

57671

-16196318

-18606098

-171552 0

-16367870

-18606098

-0.38 -0.43 43513571 43100070

6083488

6523817

2092758

3028042

8176246

9551859

-8176246

-9551859

2195

-159063

-273828

7500

-8342809

-9823492

-8342809

-9823492

-0.19 -0.23 43588381 43122671

43448317

434484

486625816

-454897093

32163207

217752 2177 445114 447291 1703931 1703931

21331

213

49965

50178

40236

402

91221

91623

-2000 -20 -11080 -11100

-7853509

43725636

437256

488904967

-462750602

26591621

1743288 1743288

23627

236

54629

54865

38562 386 100249 100635

8342809

43787825

437878

490803133

-471093411

20147600

43207183

432072

474298566

-418196412

56534226

19705 197 157757 157954 3262296 3262296

7605

52479

52555

18020

180 142980 143160

6500

29770

29835

-45965 -45965

-8782606

43259013

432590

477897883

-426979018

51351455

5500 55 13805 13860 3392706 3392706

14614

146

57371

57517

25475

255

139797

140052

-4550 -4550

-9823492

43304602

433046

481497012

-436802510

45127548

-16196318

-18606098

1973982

1867192

9545

43594

285722

402270

3436119

6655002

105043 110072

615

30793

0 366791 0 54922

-180222

-2552

-170434 -1288 2354723 -1910917

102841

46033

111515

89149

37798

222112

-12137820

-7537608

0 6152000

165032

550861

22741

-165032

5578398

9010

45965

447291 101225 0 29835

786454

761223

689615

-322942

181934

-12625794

-1777276

22672138

36060148

34282872

176743 32549 1402 374 192258 354853 0 70589 0 16268 0 4550 165000 165000

547765

578837

A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2022. In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary for a fair presentation of the Company’s financial position as of March 31, 2023 and the results of its operations for the six months then ended. The condensed balance sheet as of September 30, 2022 is derived from the September 30, 2022 audited financial statements. Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B. Summary of Significant Accounting Policies: Cash and Cash Equivalents – Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash and cash equivalents. U.S. Treasury Bills – U.S. Treasury Bills (“T-bills”) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value. Property and Equipment – Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired. Supplies used for R&D and manufacturing – Supplies are consumable items kept on hand to support the Company’s R&D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations. Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. Leases – The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.Derivative Instruments – The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, Accounting for Derivative Instruments and Hedging Activities. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period. The Company adopted Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in an Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity effective October 1, 2021. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. There was no financial impact in the period of adoption. Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, Compensation – Stock Compensation. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period. The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company’s stockholders. The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period. Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period. Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.Net Loss Per Common Share – The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive. Income Taxes – The Company accounts for income taxes in accordance with the provisions of ASC 740, "Income Taxes" ("ASC 740"), on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of March 31, 2023 and September 30, 2022. The Company adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company’s financial statements. Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes option pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. New Accounting Pronouncements - The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

Cash and Cash Equivalents – Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash and cash equivalents.

U.S. Treasury Bills – U.S. Treasury Bills (“T-bills”) are highly liquid short-term investments with maturity dates of greater than 3 months, but less than one year. These investments are recorded at fair value.

Property and Equipment – Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.

Supplies used for R&D and manufacturing – Supplies are consumable items kept on hand to support the Company’s R&D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Leases – The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.

Derivative Instruments – The Company has financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, Accounting for Derivative Instruments and Hedging Activities. In accordance with ASC 815, derivative instruments and hybrid instruments are recognized as either assets or liabilities on the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period. The Company adopted Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in an Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity effective October 1, 2021. The amendments in this Update simplify and clarify the guidance in Subtopic 815-40. There was no financial impact in the period of adoption.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, Compensation – Stock Compensation. The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized using the straight-line allocation method as expense over the requisite service or vesting period. The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company’s stockholders. The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period. Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the 2021 and 2020 Non-Qualified Stock Option Plan are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.

Net Loss Per Common Share – The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share (ASC 260). Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

Income Taxes – The Company accounts for income taxes in accordance with the provisions of ASC 740, "Income Taxes" ("ASC 740"), on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of March 31, 2023 and September 30, 2022. The Company adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes effective October 1, 2021. The new standard includes several provisions that simplify accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and increasing consistency and clarity for the users of financial statements. The adoption of ASU 2019-12 had no impact on the Company’s financial statements.

Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance, and the valuation of derivative liabilities. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. However, in regard to the valuation of derivative liabilities determined using the Black-Scholes option pricing model, significant fluctuations may materially affect the financial statements in a given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.

New Accounting Pronouncements - The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

B. LIQUIDITY The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and participation in clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from the U.S. Food and Drug Administration (FDA) for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company believes there is a high likelihood that it will continue to receive funds from private and public offerings similar to the way it has funded operations in the past. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because it showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding. Due to the Company’s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

C. STOCKHOLDERS’ EQUITY Equity Compensation Underlying share information for equity compensation plans as of March 31, 2023 is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Name of Plan</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total Shares Reserved Under Plans</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incentive Stock Option Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-Qualified Stock Option Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,787,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock Bonus Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,760</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock Compensation Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incentive Stock Bonus Plan</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> Stock option activity: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Six Months Ended March 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">122,332</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,166</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,404</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three Months Ended March 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,166</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> During the quarter ended December 31, 2021, the Company granted 250,000 performance-based stock options from the 2020 Non-Qualified Stock Option Plan to officers. Each option entitles the holder to purchase one share of the Company’s common stock at a price of $10.48 per share, the fair value on the date of issuance. The stock options will vest 100% upon approval of the first marketing application for any pharmaceutical based upon the Company’s Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. All options which have not vested as of November 18, 2031 will be canceled. On the grant date, the options were valued using a Monte Carlo Simulation approach. A Monte Carlo Simulation is a statistical technique that is used to model probabilistic systems and establish the probabilities for a variety of outcomes. However, because attainment of the performance condition cannot be considered probable, no compensation cost was recognized relating to these options as of March 31, 2023. Management will re-assess the probability of achieving the performance condition at each reporting date. Stock-Based Compensation Expense <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Six months Ended March 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Employees</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,436,119</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,655,002</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-employees</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,722</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">402,270</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three months Ended March 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Employees</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,743,288</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,392,706</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-employees</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">136,864</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">183,952</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts. Warrants and Non-Employee Options The following chart represents the warrants and non-employee options outstanding at March 31, 2023: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:14%;vertical-align:bottom;">Warrant/Options</td><td style="BORDER-BOTTOM: 1px solid;width:15%;vertical-align:bottom;">Issue Date</td><td style="BORDER-BOTTOM: 1px solid;width:13%;vertical-align:bottom;">Shares Issuable upon Exercise of Warrants/ Options</td><td style="BORDER-BOTTOM: 1px solid;width:12%;vertical-align:bottom;">Exercise Price</td><td style="BORDER-BOTTOM: 1px solid;width:14%;vertical-align:bottom;">Expiration Date</td><td style="BORDER-BOTTOM: 1px solid;width:10%;vertical-align:bottom;">Reference</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:14%;">Series N</td><td style="width:15%;">8/18/2008</td><td style="width:13%;">85,339</td><td style="width:12%;">$3.00 </td><td style="width:14%;">8/18/2024 </td><td style="width:10%;">*</td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:14%;">Series UU</td><td style="width:15%;">6/11/2018</td><td style="width:13%;">93,603</td><td style="width:12%;"> $2.80</td><td style="width:14%;">6/30/2024</td><td style="width:10%;">*</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:14%;">Series X</td><td style="width:15%;">1/13/2016</td><td style="width:13%;">120,000</td><td style="width:12%;"> $9.25 </td><td style="width:14%;">7/13/2024</td><td style="width:10%;">*</td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:14%;">Series Y</td><td style="width:15%;">2/15/2016</td><td style="width:13%;">26,000</td><td style="width:12%;">$12.00 </td><td style="width:14%;">8/15/2024</td><td style="width:10%;">*</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:14%;">Series MM</td><td style="width:15%;">6/22/2017</td><td style="width:13%;">333,432</td><td style="width:12%;">$1.86 </td><td style="width:14%;">6/22/2024</td><td style="width:10%;">*</td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:14%;">Series NN</td><td style="width:15%;">7/24/2017</td><td style="width:13%;">200,087</td><td style="width:12%;">$2.52 </td><td style="width:14%;">7/24/2024</td><td style="width:10%;"> *</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:14%;">Series RR</td><td style="width:15%;">10/30/2017</td><td style="width:13%;">234,009</td><td style="width:12%;">$1.65 </td><td style="width:14%;">10/30/2024</td><td style="width:10%;">*</td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:14%;">Series TT</td><td style="width:15%;">2/5/2018</td><td style="width:13%;">-</td><td style="width:12%;">$2.24 </td><td style="width:14%;">2/5/2023</td><td style="width:10%;">2</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:14%;">Consultant Options</td><td style="width:15%;">7/28/2017 </td><td style="width:13%;">10,000</td><td style="width:12%;"> $2.18 </td><td style="width:14%;">7/27/2027</td><td style="width:10%;">*</td></tr></tbody></table>* No current period changes for these warrants1. Derivative Liabilities The table below presents the gains on the warrant liabilities for the six months ended March 31: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Z warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,787</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series AA warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">274,635</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series CC warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,372</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series HH warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net gain on warrant liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">366,791</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The table below presents the gains on the warrant liabilities for the three months ended March 31: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series AA warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series HH warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">795</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net gain on warrant liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,195</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded. In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss. Changes in Warrant Liabilities As of March 31, 2023, no warrant liabilities were outstanding. During the six months ended March 31, 2022, 15,205 Series CC warrants were exercised at an exercise price of $5.00 for gross proceeds of $76,025. No Series CC warrants were exercised during the three months ended March 31, 2022. In February 2022, 100,000 Series AA warrants with, an exercise price of $13.75 and 200 Series HH warrants with an exercise price of $3.13, expired. In December 2021, 640 Series CC warrants, with an exercise price of $5.00, expired. In November 2021, 184,800 Series Z warrants, with an exercise price of $13.75, expired. 2. Equity Warrants Changes in Equity Warrants On February 5, 2023, 600 Series TT warrants, with an exercise price of $2.24, expired. During the six months ended March 31, 2023, 17,752 Series RR warrants at an exercise price of $1.65 and 200,000 Series SS warrants at an exercise price of $2.09 were exercised for gross proceeds of $447,291. No series RR or SS warrants were exercised during the three months ended March 31, 2023. During the six months ended March 31, 2022, 10,000 Series NN warrants were exercised at an exercise price of $2.52 for gross proceeds of $25,200. During the three months ended March 31, 2022, 5,500 Series NN warrants were exercised at an exercise price of $2.52 for gross proceeds of $13,860.On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary. 3. Options and Shares Issued to Consultants During the six months ended March 31, 2023 and 2022, the Company issued 78,798 and 43,495 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $2.47 and $7.05 during the six months ended March 31, 2023 and 2022, respectively. During the three months ended March 31, 2023 and 2022, the Company issued 38,562 and 25,475 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $2.42 and $5.00, respectively, during the three months ended March 31, 2023 and 2022. The aggregate values of the issuances of restricted common stock and common stock options are recorded as prepaid expenses and are charged to general and administrative expenses over the periods of service. During the six months ended March 31, 2023, 5,000 options with an exercise price of $11.61 issued to a consultant expired. As of March 31, 2023, 10,000 options issued to consultants remained outstanding, all of which were issued from the Non-Qualified Stock Option plans. All 10,000 options are vested as of March 31, 2023. During the six months ended March 31, 2023 and 2022, the Company recorded total expense of approximately $285,000 and $402,000, respectively, relating to the share-based compensation under these consulting agreements. On March 31, 2023 and September 30, 2022, consulting fees of approximately $311,000 and $295,000, respectively, are included in prepaid expenses and will be amortized over the remaining service periods.

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Name of Plan</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total Shares Reserved Under Plans</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incentive Stock Option Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Non-Qualified Stock Option Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,787,200</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock Bonus Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">783,760</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock Compensation Plans</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Incentive Stock Bonus Plan</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

138400

13787200

783760

634000

640000

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Six Months Ended March 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">252,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">122,332</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,166</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,404</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three Months Ended March 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"> 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,500</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options forfeited</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,500</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,166</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

4500

252500

6500

122332

20166

45404

2000

1500

25500

7166

250000 10.48 1

3436119

6655002

285722

402270

1743288

3392706

136864

183952

<table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:14%;vertical-align:bottom;">Warrant/Options</td><td style="BORDER-BOTTOM: 1px solid;width:15%;vertical-align:bottom;">Issue Date</td><td style="BORDER-BOTTOM: 1px solid;width:13%;vertical-align:bottom;">Shares Issuable upon Exercise of Warrants/ Options</td><td style="BORDER-BOTTOM: 1px solid;width:12%;vertical-align:bottom;">Exercise Price</td><td style="BORDER-BOTTOM: 1px solid;width:14%;vertical-align:bottom;">Expiration Date</td><td style="BORDER-BOTTOM: 1px solid;width:10%;vertical-align:bottom;">Reference</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:14%;">Series N</td><td style="width:15%;">8/18/2008</td><td style="width:13%;">85,339</td><td style="width:12%;">$3.00 </td><td style="width:14%;">8/18/2024 </td><td style="width:10%;">*</td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:14%;">Series UU</td><td style="width:15%;">6/11/2018</td><td style="width:13%;">93,603</td><td style="width:12%;"> $2.80</td><td style="width:14%;">6/30/2024</td><td style="width:10%;">*</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:14%;">Series X</td><td style="width:15%;">1/13/2016</td><td style="width:13%;">120,000</td><td style="width:12%;"> $9.25 </td><td style="width:14%;">7/13/2024</td><td style="width:10%;">*</td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:14%;">Series Y</td><td style="width:15%;">2/15/2016</td><td style="width:13%;">26,000</td><td style="width:12%;">$12.00 </td><td style="width:14%;">8/15/2024</td><td style="width:10%;">*</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:14%;">Series MM</td><td style="width:15%;">6/22/2017</td><td style="width:13%;">333,432</td><td style="width:12%;">$1.86 </td><td style="width:14%;">6/22/2024</td><td style="width:10%;">*</td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:14%;">Series NN</td><td style="width:15%;">7/24/2017</td><td style="width:13%;">200,087</td><td style="width:12%;">$2.52 </td><td style="width:14%;">7/24/2024</td><td style="width:10%;"> *</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:14%;">Series RR</td><td style="width:15%;">10/30/2017</td><td style="width:13%;">234,009</td><td style="width:12%;">$1.65 </td><td style="width:14%;">10/30/2024</td><td style="width:10%;">*</td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:14%;">Series TT</td><td style="width:15%;">2/5/2018</td><td style="width:13%;">-</td><td style="width:12%;">$2.24 </td><td style="width:14%;">2/5/2023</td><td style="width:10%;">2</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:14%;">Consultant Options</td><td style="width:15%;">7/28/2017 </td><td style="width:13%;">10,000</td><td style="width:12%;"> $2.18 </td><td style="width:14%;">7/27/2027</td><td style="width:10%;">*</td></tr></tbody></table> 8/18/2008 85339 3.00 8/18/2024 6/11/2018 93603 2.80 6/30/2024 1/13/2016 120000 9.25 7/13/2024 2/15/2016 26000 12.00 8/15/2024 6/22/2017 333432 1.86 6/22/2024 7/24/2017 200087 2.52 7/24/2024 10/30/2017 234009 1.65 10/30/2024 2/5/2018 2.24 2/5/2023 7/28/2017 10000 2.18 7/27/2027 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series Z warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,787</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series AA warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">274,635</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series CC warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,372</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series HH warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,597</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net gain on warrant liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">366,791</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Series AA warrants </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,400</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Series HH warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">795</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net gain on warrant liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,195</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 0 64787 0 274635 0 24372 0 1597 0 366791 0 1400 0 795 0 2195 15205 5.00 76025 100000 13.75 200 640 5.00 184800 13.75 600 2.24 17752 1.65 200000 2.09 447291 10000 2.52 25200 5500 2.52 13860 172000

78798

43495

2.47

7.05

38562

25475

2.42

5.00

5000

11.61

285000

402000

311000 295000

D. FAIR VALUE MEASUREMENTS In accordance with ASC 820-10, Fair Value Measurements, the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts. ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">●</td><td style="vertical-align:top;">Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">●</td><td style="vertical-align:top;">Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">●</td><td style="vertical-align:top;">Level 3 – Unobservable inputs that reflect management’s assumptions. Assumptions from market participants are used when pricing the asset or liabilities, given there is no readily available market information.</td></tr></tbody></table> For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of an input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.The following sets forth a reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for both the six and three months ended March 31, 2023 and 2022: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Six months ended March 31, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Six months ended March 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Beginning balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issuances</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercises</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(70,589</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Realized and unrealized (gains) and losses</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(366,791</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Ending balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Three months ended March 31, 2023</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Three months ended March 31, 2022</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Beginning balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,195</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issuances</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercises</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Realized and unrealized (gains) and losses</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,195</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Ending balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The fair values of the Company’s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock, as well as U.S. Treasury Bill rates. At March 31, 2023 and September 30, 2022, the Company did not have any Level 3 derivative instruments.

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Six months ended March 31, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Six months ended March 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Beginning balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">437,380</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issuances</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercises</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(70,589</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Realized and unrealized (gains) and losses</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(366,791</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Ending balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Three months ended March 31, 2023</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 1px solid;">Three months ended March 31, 2022</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Beginning balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,195</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issuances</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercises</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Realized and unrealized (gains) and losses</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,195</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Ending balance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

437380

70589

-366791

0 0

2195

-2195

E. RELATED PARTY TRANSACTIONS On October 28, 2022, the expiration dates of the Series RR warrants held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company’s CEO, Geert Kersten, is a beneficiary were extended by two years. The incremental cost of these modifications was $172,552 and was recorded as a deemed dividend in the financial statements for the six months ended March 31, 2023.

172552

F. COMMITMENTS AND CONTINGENCIES Clinical Research Agreement Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company’s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808 “Collaborative Arrangements”. The Company determined the payments to Ergomed are within the scope of ASC 730 Research and Development. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.6 million for Ergomed’s services. This amount is net of Ergomed’s discount of approximately $11.8 million. During the six months ended March 31, 2023 and 2022, the Company recorded, net of Ergomed’s discount, approximately $0.1 million and $0.4 million, respectively, as research and development expense related to Ergomed’s services. During the three months ended March 31, 2023 and 2022, the Company recorded, net of Ergomed’s discount, approximately $0.0 million and $0.2 million, respectively, as research and development expense related to Ergomed’s services.Lease Agreements The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain. On March 31, 2023 and September 30, 2022, the net book value of the finance lease right of use asset is approximately $10.0 million and $10.9 million, respectively and the balance of the finance lease liability is approximately $12.5 million and $13.3 million, respectively, of which approximately $1.6 million is current in each quarter. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the six months ended March 31, 2023 and 2022 was approximately $1.3 million for both periods, respectively, of which approximately $0.6 million was for interest in each six-month period. As of March 31, 2023, the weighted average discount rate of the Company’s finance leases is 8.45% and the weighted average time to maturity is 5.6 years. In August 2020, the Company entered into an amendment to the San Tomas lease under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The project was finished and the improvements were placed in service in October 2021. Total cost was $11.1 million, of which the landlord agreed to finance $2.4 million. The landlord financing is being repaid through increased lease payments which started in March 2021 and extend over the remaining lease term. The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year. The Company remeasured the lease liability to account for the modified payments using a 8.45% implicit interest rate. The rate was determined using a synthetic credit rating analysis prepared by an outside valuation specialist. Additionally, this financing is considered to be a lease incentive from the landlord and has been included in the calculation of the lease liability as it is realized. The entire $2.4 million was received from the landlord as of September 30, 2022. The leasehold improvements are recorded in property and equipment, were deemed to be placed in service in October 2021 and are being amortized over the remaining lease term. On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year’s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned. Approximate future minimum lease payments under finance leases as of March 31, 2023 are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Six months ending September 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,291,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Year ending September 30,</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,655,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,741,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,832,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2027</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,923,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2028</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,015,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">252,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total future minimum lease obligation </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,709,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Less imputed interest on finance lease obligations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,189,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Net present value of finance lease obligations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,520,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>The Company leases two facilities under operating leases. The lease for the Company’s office headquarters will expire on November 30, 2025. The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. This resulted in an increase of approximately $1.1 million to the operating lease right of use asset and liability. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. As of March 31, 2023 and September 30, 2022, the net book value of the operating lease right of use assets is approximately $1.8 million and $1.9 million, respectively. As of March 31, 2023 and September 30, 2022, the balance of the operating lease liabilities is approximately $1.9 million and $2.0 million, respectively, of which approximately $0.2 million, is current as of each reporting date. The Company incurred lease expense for operating leases of approximately $0.1 million and $0.2 million for the six months ended March 31, 2023 and 2022, respectively. Total cash paid related to operating leases during the six months ended March 31, 2023 and 2022 was approximately $0.2 and $0.1 million, respectively. The weighted average discount rate of the Company’s operating leases is 10.2% and the weighted average time to maturity is 8.14 years. As of March 31, 2023, future minimum lease payments on operating leases are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Six months ending September 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">176,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Year ending September 30,</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2027</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2028</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,040,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total future minimum lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,788,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less imputed interest on operating lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(849,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net present value of operating lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,939,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

12000000

3560000

1180000

100000

4000

0.0

2000

1000000.0 109000 1250000 1330000 1300000 60000

0.0845

P5Y7M6D 1110000 240000 The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year

0.084

230000

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Six months ending September 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,291,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Year ending September 30,</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,655,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,741,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,832,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> 2027</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,923,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> 2028</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,015,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">252,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Total future minimum lease obligation </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,709,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"> Less imputed interest on finance lease obligations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,189,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"> Net present value of finance lease obligations</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,520,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

1291000

2655000

2741000

2832000

2923000

3015000

252000

15709000

3189000

12520000 110000 180000 190000

190000

200000.0

20000

100000

200000

100000

0.102

P8Y1M20D

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Six months ending September 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">176,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Year ending September 30,</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">357,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2027</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2028</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,040,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total future minimum lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,788,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less imputed interest on operating lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(849,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net present value of operating lease obligation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,939,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

176000

357000

366000

287000

277000

285000

1040000

2788000

849000

1939000

G. PATENTS During the six months ended March 31, 2023 and 2022, the Company recorded approximately $0 and $31,000 in patent impairment charges. No patent impairment charges were recorded during the three months ended March 31, 2023 and 2022. For the six months ended March 31, 2023 and 2022, amortization of patent costs totaled approximately $20,000 and $27,000, respectively. For the three months ended March 31, 2023 and 2022, amortization of patent costs totaled approximately $10,000 and $13,000, respectively. Approximate estimated future amortization expense is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Six months ending September 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Year ending September 30,</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2027</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2028</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">192,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

0 31000

20000

27000

10000

13000

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Six months ending September 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Year ending September 30,</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2027</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2028</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Thereafter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">192,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

18000

30000

28000

24000

21000

17000

54000

192000

H. LOSS PER COMMON SHARE Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. The following tables provide the details of the basic and diluted loss per-share computations: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Six months ended March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three months ended March 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023 </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023 </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Loss per share – basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss available to common shareholders – basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(16,367,869</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(18,606,098</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,342,809</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9,823,492</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average shares outstanding – basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,513,571</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,100,070</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,588,381</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,122,671</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Basic and diluted loss per common share</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.38</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.43</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.19</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.23</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> In accordance with the contingently issuable shares guidance of ASC Topic 260, Earnings Per Share, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of March 31: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options and Warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,893,248</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,586,365</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Unvested Restricted Stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">149,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,042,498</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,737,615</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Six months ended March 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Three months ended March 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023 </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023 </td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Loss per share – basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss available to common shareholders – basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(16,367,869</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(18,606,098</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,342,809</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9,823,492</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average shares outstanding – basic and diluted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,513,571</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,100,070</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,588,381</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,122,671</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Basic and diluted loss per common share</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.38</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.43</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.19</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.23</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> -16367869 -18606098 -8342809 -9823492 43513571 43100070 43588381 43122671 -0.38 -0.43 -0.19 -0.23 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options and Warrants</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,893,248</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,586,365</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Unvested Restricted Stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">149,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,042,498</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">12,737,615</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

13893248

12586365

149250

151250

14042498

12737615

J. SUBSEQUENT EVENTS On April 27, 2023, the Company sold 794,117 shares of common stock at a public offering price of $1.70 per share and received aggregate net proceeds of approximately $1.1 million. The Company granted the underwriters a 30-day option to purchase up to 119,117 additional shares of common stock to cover over-allotments. The underwriter fully exercised this option on May 2, 2023 resulting in additional net proceeds to the Company of approximately $190,000.

794117 1.70 1100000 119117 190000 EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 103 259 1 false 32 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://cvm.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONDENSED BALANCE SHEETS Sheet http://cvm.com/role/CondensedBalanceSheets CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://cvm.com/role/CondensedBalanceSheetsParenthetical CONDENSED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://cvm.com/role/CondensedStatementsOfOperationsUnaudited CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) Sheet http://cvm.com/role/StatementsOfStockholdersEquityUnaudited STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) Statements 5 false false R6.htm 000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 000008 - Disclosure - LIQUIDITY Sheet http://cvm.com/role/LIQUIDITY LIQUIDITY Notes 8 false false R9.htm 000009 - Disclosure - STOCKHOLDERS EQUITY Sheet http://cvm.com/role/StockholdersEquity STOCKHOLDERS EQUITY Notes 9 false false R10.htm 000010 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://cvm.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 10 false false R11.htm 000011 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://cvm.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 11 false false R12.htm 000012 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://cvm.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 000013 - Disclosure - PATENTS Sheet http://cvm.com/role/PATENTS PATENTS Notes 13 false false R14.htm 000014 - Disclosure - LOSS PER COMMON SHARE Sheet http://cvm.com/role/LossPerCommonShare LOSS PER COMMON SHARE Notes 14 false false R15.htm 000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://cvm.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 000017 - Disclosure - STOCKHOLDERS EQUITY (Tables) Sheet http://cvm.com/role/StockholdersEquityTables STOCKHOLDERS EQUITY (Tables) Tables http://cvm.com/role/StockholdersEquity 17 false false R18.htm 000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://cvm.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://cvm.com/role/FairValueMeasurements 18 false false R19.htm 000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://cvm.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://cvm.com/role/CommitmentsAndContingencies 19 false false R20.htm 000020 - Disclosure - PATENTS (Tables) Sheet http://cvm.com/role/PatentsTables PATENTS (Tables) Tables http://cvm.com/role/PATENTS 20 false false R21.htm 000021 - Disclosure - LOSS PER COMMON SHARE (Tables) Sheet http://cvm.com/role/LossPerCommonShareTables LOSS PER COMMON SHARE (Tables) Tables http://cvm.com/role/LossPerCommonShare 21 false false R22.htm 000022 - Disclosure - STOCKHOLDERS EQUITY (Details) Sheet http://cvm.com/role/StockholdersEquityDetails STOCKHOLDERS EQUITY (Details) Details http://cvm.com/role/StockholdersEquityTables 22 false false R23.htm 000023 - Disclosure - STOCKHOLDERS EQUITY (Details 1) Sheet http://cvm.com/role/StockholdersEquityDetails1 STOCKHOLDERS EQUITY (Details 1) Details http://cvm.com/role/StockholdersEquityTables 23 false false R24.htm 000024 - Disclosure - STOCKHOLDERS EQUITY (Details 2) Sheet http://cvm.com/role/StockholdersEquityDetails2 STOCKHOLDERS EQUITY (Details 2) Details http://cvm.com/role/StockholdersEquityTables 24 false false R25.htm 000025 - Disclosure - STOCKHOLDERS EQUITY (Details 3) Sheet http://cvm.com/role/StockholdersEquityDetails3 STOCKHOLDERS EQUITY (Details 3) Details http://cvm.com/role/StockholdersEquityTables 25 false false R26.htm 000026 - Disclosure - STOCKHOLDERS EQUITY (Details 4) Sheet http://cvm.com/role/StockholdersEquityDetails4 STOCKHOLDERS EQUITY (Details 4) Details http://cvm.com/role/StockholdersEquityTables 26 false false R27.htm 000027 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative) Sheet http://cvm.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS EQUITY (Details Narrative) Details http://cvm.com/role/StockholdersEquityTables 27 false false R28.htm 000028 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://cvm.com/role/FairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) Details http://cvm.com/role/FairValueMeasurementsTables 28 false false R29.htm 000029 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative ) Sheet http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative ) Details http://cvm.com/role/RelatedPartyTransactions 29 false false R30.htm 000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://cvm.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://cvm.com/role/CommitmentsAndContingenciesTables 30 false false R31.htm 000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1) Sheet http://cvm.com/role/CommitmentsAndContingenciesDetails1 COMMITMENTS AND CONTINGENCIES (Details 1) Details http://cvm.com/role/CommitmentsAndContingenciesTables 31 false false R32.htm 000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://cvm.com/role/CommitmentsAndContingenciesTables 32 false false R33.htm 000033 - Disclosure - PATENTS (Details) Sheet http://cvm.com/role/PatentsDetails PATENTS (Details) Details http://cvm.com/role/PatentsTables 33 false false R34.htm 000034 - Disclosure - PATENTS (Details Narrative) Sheet http://cvm.com/role/PatentsDetailsNarrative PATENTS (Details Narrative) Details http://cvm.com/role/PatentsTables 34 false false R35.htm 000035 - Disclosure - LOSS PER COMMON SHARE (Details) Sheet http://cvm.com/role/LossPerCommonShareDetails LOSS PER COMMON SHARE (Details) Details http://cvm.com/role/LossPerCommonShareTables 35 false false R36.htm 000036 - Disclosure - LOSS PER COMMON SHARE (Details 1) Sheet http://cvm.com/role/LossPerCommonShareDetails1 LOSS PER COMMON SHARE (Details 1) Details http://cvm.com/role/LossPerCommonShareTables 36 false false R37.htm 000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://cvm.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://cvm.com/role/SubsequentEvents 37 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept DueToEmployeesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. cvm_10q.htm 1 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 11 fact(s) appearing in ix:hidden were eligible for transformation: cvm:CashPaidRelatedToFinanceLeases, cvm:CurrentBalance, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding - cvm_10q.htm 1 cvm_10q.htm cvm-20230331.xsd cvm-20230331_cal.xml cvm-20230331_def.xml cvm-20230331_lab.xml cvm-20230331_pre.xml cvm_ex31.htm cvm_ex32.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cvm_10q.htm": { "axisCustom": 0, "axisStandard": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 330, "http://xbrl.sec.gov/dei/2022": 30 }, "contextCount": 103, "dts": { "calculationLink": { "local": [ "cvm-20230331_cal.xml" ] }, "definitionLink": { "local": [ "cvm-20230331_def.xml" ] }, "inline": { "local": [ "cvm_10q.htm" ] }, "labelLink": { "local": [ "cvm-20230331_lab.xml" ] }, "presentationLink": { "local": [ "cvm-20230331_pre.xml" ] }, "schema": { "local": [ "cvm-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 342, "entityCount": 1, "hidden": { "http://cvm.com/20230331": 2, "http://fasb.org/us-gaap/2022": 9, "http://xbrl.sec.gov/dei/2022": 5, "total": 16 }, "keyCustom": 90, "keyStandard": 169, "memberCustom": 27, "memberStandard": 5, "nsprefix": "cvm", "nsuri": "http://cvm.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "strong", "span", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://cvm.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "strong", "span", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - FAIR VALUE MEASUREMENTS", "menuCat": "Notes", "order": "10", "role": "http://cvm.com/role/FairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "11", "role": "http://cvm.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "12", "role": "http://cvm.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - PATENTS", "menuCat": "Notes", "order": "13", "role": "http://cvm.com/role/PATENTS", "shortName": "PATENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - LOSS PER COMMON SHARE", "menuCat": "Notes", "order": "14", "role": "http://cvm.com/role/LossPerCommonShare", "shortName": "LOSS PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "15", "role": "http://cvm.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "16", "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - STOCKHOLDERS EQUITY (Tables)", "menuCat": "Tables", "order": "17", "role": "http://cvm.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "menuCat": "Tables", "order": "18", "role": "http://cvm.com/role/FairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "menuCat": "Tables", "order": "19", "role": "http://cvm.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONDENSED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://cvm.com/role/CondensedBalanceSheets", "shortName": "CONDENSED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - PATENTS (Tables)", "menuCat": "Tables", "order": "20", "role": "http://cvm.com/role/PatentsTables", "shortName": "PATENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - LOSS PER COMMON SHARE (Tables)", "menuCat": "Tables", "order": "21", "role": "http://cvm.com/role/LossPerCommonShareTables", "shortName": "LOSS PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2023-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - STOCKHOLDERS EQUITY (Details)", "menuCat": "Details", "order": "22", "role": "http://cvm.com/role/StockholdersEquityDetails", "shortName": "STOCKHOLDERS EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2023-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfStockOptionActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - STOCKHOLDERS EQUITY (Details 1)", "menuCat": "Details", "order": "23", "role": "http://cvm.com/role/StockholdersEquityDetails1", "shortName": "STOCKHOLDERS EQUITY (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfStockOptionActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensatingBalancesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - STOCKHOLDERS EQUITY (Details 2)", "menuCat": "Details", "order": "24", "role": "http://cvm.com/role/StockholdersEquityDetails2", "shortName": "STOCKHOLDERS EQUITY (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensatingBalancesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31_cvm_ConsultantsOptionMember", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:IssueDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - STOCKHOLDERS EQUITY (Details 3)", "menuCat": "Details", "order": "25", "role": "http://cvm.com/role/StockholdersEquityDetails3", "shortName": "STOCKHOLDERS EQUITY (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31_cvm_ConsultantsOptionMember", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:IssueDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:FairValueOfSeriesZwarrants", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - STOCKHOLDERS EQUITY (Details 4)", "menuCat": "Details", "order": "26", "role": "http://cvm.com/role/StockholdersEquityDetails4", "shortName": "STOCKHOLDERS EQUITY (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "cvm:GainLossOnDerivativeInstrumentsNetPretax1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:IncrementalCostDeemedDividend", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://cvm.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:IncrementalCostDeemedDividend", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - FAIR VALUE MEASUREMENTS (Details)", "menuCat": "Details", "order": "28", "role": "http://cvm.com/role/FairValueMeasurementsDetails", "shortName": "FAIR VALUE MEASUREMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2022-10-28_cvm_CEOGeertKerstenMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )", "menuCat": "Details", "order": "29", "role": "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative )", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2022-10-28_cvm_CEOGeertKerstenMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://cvm.com/role/CondensedBalanceSheetsParenthetical", "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:FinanceLeaseLiabilityPaymentsDueRemainderOfYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "menuCat": "Details", "order": "30", "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:FinanceLeaseLiabilityPaymentsDueRemainderOfYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2023-12-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)", "menuCat": "Details", "order": "31", "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails1", "shortName": "COMMITMENTS AND CONTINGENCIES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2023-12-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "-4", "first": true, "lang": null, "name": "cvm:NetOfDiscount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "-4", "first": true, "lang": null, "name": "cvm:NetOfDiscount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - PATENTS (Details)", "menuCat": "Details", "order": "33", "role": "http://cvm.com/role/PatentsDetails", "shortName": "PATENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:PatentImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - PATENTS (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://cvm.com/role/PatentsDetailsNarrative", "shortName": "PATENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:PatentImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - LOSS PER COMMON SHARE (Details)", "menuCat": "Details", "order": "35", "role": "http://cvm.com/role/LossPerCommonShareDetails", "shortName": "LOSS PER COMMON SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfAntiDilutiveSecuritiestabletextblock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - LOSS PER COMMON SHARE (Details 1)", "menuCat": "Details", "order": "36", "role": "http://cvm.com/role/LossPerCommonShareDetails1", "shortName": "LOSS PER COMMON SHARE (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "cvm:ScheduleOfAntiDilutiveSecuritiestabletextblock", "ix:continuation", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2023-04-01to2023-04-27_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "cvm:CommonStockSold", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "menuCat": "Details", "order": "37", "role": "http://cvm.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2023-04-01to2023-04-27_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "cvm:CommonStockSold", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)", "menuCat": "Statements", "order": "4", "role": "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "shortName": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "AsOf2021-09-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)", "menuCat": "Statements", "order": "5", "role": "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited", "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2021-10-01to2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "lang": null, "name": "cvm:WarrantExercisesShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)", "menuCat": "Statements", "order": "6", "role": "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited", "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "7", "role": "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:LiquiditydisclosureTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - LIQUIDITY", "menuCat": "Notes", "order": "8", "role": "http://cvm.com/role/LIQUIDITY", "shortName": "LIQUIDITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "cvm:LiquiditydisclosureTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - STOCKHOLDERS EQUITY", "menuCat": "Notes", "order": "9", "role": "http://cvm.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cvm_10q.htm", "contextRef": "From2022-10-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 32, "tag": { "cvm_AccruedConsultingServicesToBePaidWithCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued consulting services to be paid with common stock" } } }, "localname": "AccruedConsultingServicesToBePaidWithCommonStock", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_AdditionalNetProceed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Additional Net Proceed" } } }, "localname": "AdditionalNetProceed", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_AdditionalSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional shares of common stock" } } }, "localname": "AdditionalSharesOfCommonStock", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_BalanceOfTheFinanceLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Balance Of The Finance Lease Liability" } } }, "localname": "BalanceOfTheFinanceLeaseLiability", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_CEOGeertKerstenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CEO, Geert Kersten [Member]" } } }, "localname": "CEOGeertKerstenMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_CashPaidRelatedToFinanceLeases": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cash Paid Related To Finance Leases" } } }, "localname": "CashPaidRelatedToFinanceLeases", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_CashPaidRelatedToFinanceLeasesInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash Paid Related To Finance Leases Interest" } } }, "localname": "CashPaidRelatedToFinanceLeasesInterest", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants exercised" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantExercised", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_ClinicalServiceTrial": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Clinical Service Trial" } } }, "localname": "ClinicalServiceTrial", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_CommonStockContributedToEmployeeBenefitPlan": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Common stock contributed to 401(k) plan" } } }, "localname": "CommonStockContributedToEmployeeBenefitPlan", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_CommonStockPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock price" } } }, "localname": "CommonStockPrice", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "cvm_CommonStockSold": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock sold" } } }, "localname": "CommonStockSold", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_ConsultantsOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultants Options [Member]" } } }, "localname": "ConsultantsOptionMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_ConsultingAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreements [Member]" } } }, "localname": "ConsultingAgreementsMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_ConsultingFeesIncluedPrepaidExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Consulting fees inclued prepaid expenses" } } }, "localname": "ConsultingFeesIncluedPrepaidExpenses", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_CurrentBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Current Balance" } } }, "localname": "CurrentBalance", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_CurrentPortionOfOperatingLeaseObligation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Current portion of the operating lease obligation" } } }, "localname": "CurrentPortionOfOperatingLeaseObligation", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_DepositAssetsCurrent": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deposits" } } }, "localname": "DepositAssetsCurrent", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cvm_DerivativeLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities" } } }, "localname": "DerivativeLiabilitiesMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails4" ], "xbrltype": "domainItemType" }, "cvm_EquityBasedCompensationEmployees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Equity based compensation - employees" } } }, "localname": "EquityBasedCompensationEmployees", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ErgomedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ergomed [Member]" } } }, "localname": "ErgomedMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_ExerciseOfDerivativeLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Exercise of derivative liabilities" } } }, "localname": "ExerciseOfDerivativeLiabilities", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "localname": "ExercisePrice", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3" ], "xbrltype": "perShareItemType" }, "cvm_ExercisePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise price per share" } } }, "localname": "ExercisePricePerShare", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "cvm_ExercisePriceWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Exercise Price]", "verboseLabel": "Exercise Price" } } }, "localname": "ExercisePriceWarrants", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "cvm_ExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "localname": "ExpirationDate", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3" ], "xbrltype": "stringItemType" }, "cvm_FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Realized And Unrealized (gains) And Losses" } } }, "localname": "FairValueMeasuredOnRecurringBasisGainLossIncludedEarnings", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "cvm_FairValueOfSeriesAaWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series AA Warrants" } } }, "localname": "FairValueOfSeriesAaWarrants", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_FairValueOfSeriesCcWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series CC Warrants" } } }, "localname": "FairValueOfSeriesCcWarrants", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_FairValueOfSeriesHhWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series HH Warrants" } } }, "localname": "FairValueOfSeriesHhWarrants", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_FairValueOfSeriesZwarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Series Z Warrants" } } }, "localname": "FairValueOfSeriesZwarrants", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_FinanceLeaseLiabilityPaymentsDueRemainderOfYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Six months ending September 30, 2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueRemainderOfYear", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "cvm_FinanceLeaseObligationIncludedInAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Finance lease obligation included in accounts payable" } } }, "localname": "FinanceLeaseObligationIncludedInAccountsPayable", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_FinancingArrangementDepositBaseRentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Financing arrangement deposit base rent amount" } } }, "localname": "FinancingArrangementDepositBaseRentAmount", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_FinancingArrangementDepositBaseRentPercentageDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing arrangement deposit base rent percentage description" } } }, "localname": "FinancingArrangementDepositBaseRentPercentageDescription", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "cvm_FinancingCostsIncludedInCurrentLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Financing costs included in current liabilities" } } }, "localname": "FinancingCostsIncludedInCurrentLiabilities", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_FinancingLeaseContractualArrangement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Financing Arrangement" } } }, "localname": "FinancingLeaseContractualArrangement", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_GainLossOnDerivativeInstrumentsNetPretax1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net Gain On Warrant Liabilities" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax1", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails4" ], "xbrltype": "monetaryItemType" }, "cvm_GainOnDerivativeInstruments": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Gain on derivative instruments]", "negatedLabel": "Gain on derivative instruments" } } }, "localname": "GainOnDerivativeInstruments", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_GrantPerformanceBasedStockOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Grant performance-based stock options" } } }, "localname": "GrantPerformanceBasedStockOptions", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "cvm_IncentiveStockBonusPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Stock Bonus Plan [Member]" } } }, "localname": "IncentiveStockBonusPlansMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "cvm_IncentiveStockForfeitedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "2014 Incentive Stock Forfeited, amount" } } }, "localname": "IncentiveStockForfeitedAmount", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_IncentiveStockForfeitedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2014 Incentive Stock Forfeited, shares" } } }, "localname": "IncentiveStockForfeitedShares", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted loss per common share" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShares", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/LossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "cvm_IncreaseDecreaseInDepositAssets": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Deposits]", "negatedLabel": "Deposits" } } }, "localname": "IncreaseDecreaseInDepositAssets", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_IncreaseDecreaseInSuppliesUsedForRDAndManufacturing": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Supplies used for R&D and manufacturing 1]", "negatedLabel": "Supplies used for R&D and manufacturing" } } }, "localname": "IncreaseDecreaseInSuppliesUsedForRDAndManufacturing", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_IncreaseInRightOfUseAssetAndLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Increase In Right Of Use Asset And Liability" } } }, "localname": "IncreaseInRightOfUseAssetAndLiability", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_IncrementalCostDeemedDividend": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Incremental cost" } } }, "localname": "IncrementalCostDeemedDividend", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_IssueDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issue Date" } } }, "localname": "IssueDate1", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3" ], "xbrltype": "stringItemType" }, "cvm_LIQUIDITYAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIQUIDITY" } } }, "localname": "LIQUIDITYAbstract", "nsuri": "http://cvm.com/20230331", "xbrltype": "stringItemType" }, "cvm_LandlordMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Landlord [Member]" } } }, "localname": "LandlordMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_LeaseLiabilitiesCurrentPortion": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Lease liabilities, current portion" } } }, "localname": "LeaseLiabilitiesCurrentPortion", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cvm_LeasesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "LeasesPolicyTextBlock", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cvm_LesseeOperatingLeaseLiabilityPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Total Future Minimum Lease Obligation]", "verboseLabel": "Total Future Minimum Lease Obligation" } } }, "localname": "LesseeOperatingLeaseLiabilityPayments", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "cvm_LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Six months ending September 30, 2023]", "verboseLabel": "Six months ending September 30, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfYear", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "cvm_LiquiditydisclosureTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[LIQUIDITY]", "verboseLabel": "LIQUIDITY" } } }, "localname": "LiquiditydisclosureTextblock", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/LIQUIDITY" ], "xbrltype": "textBlockItemType" }, "cvm_LossOnReceivables": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Loss on Receivables" } } }, "localname": "LossOnReceivables", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ModificationOfFinanceLeases": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Modification of finance leases" } } }, "localname": "ModificationOfFinanceLeases", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ModificationOfWarrants": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Modification of warrants" } } }, "localname": "ModificationOfWarrants", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_NetBookValueOfTheFinanceLeaseRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net Book Value Of The Finance Lease Right Of Use Asset" } } }, "localname": "NetBookValueOfTheFinanceLeaseRightOfUseAsset", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net loss available to common shareholders - basic and diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/LossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "cvm_NetLossPerCommonShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per common share - basic and diluted" } } }, "localname": "NetLossPerCommonShareBasicAndDiluted", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "cvm_NetOfDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net Of Discount" } } }, "localname": "NetOfDiscount", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_NetPresentValueOfLeaseFinanceLeaseObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net Present Value Of Finance Lease Obligations" } } }, "localname": "NetPresentValueOfLeaseFinanceLeaseObligations", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "cvm_NetProceed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net proceed" } } }, "localname": "NetProceed", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_NonQualifiedStockOptionsPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-Qualified Stock Option Plans [Member]" } } }, "localname": "NonQualifiedStockOptionsPlansMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_OperatingLeaseRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operating Lease Right Of Use Assets" } } }, "localname": "OperatingLeaseRightOfUseAssets", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_OptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options and Warrants" } } }, "localname": "OptionsMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/LossPerCommonShareDetails1" ], "xbrltype": "domainItemType" }, "cvm_PatentImpairmentCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Patent Impairment Charges" } } }, "localname": "PatentImpairmentCharges", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/PatentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_PaymentsMadeByLandlord": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Payments Made By Landlord" } } }, "localname": "PaymentsMadeByLandlord", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_PrepaidConsultingServicesPaidWithIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid consulting services paid with issuance of common stock" } } }, "localname": "PrepaidConsultingServicesPaidWithIssuanceOfCommonStock", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ProceedsFromExercisesOfWarrantsAndOptions": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from exercises of warrants" } } }, "localname": "ProceedsFromExercisesOfWarrantsAndOptions", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ProceedsFromMaturityOfUsTreasuryBills": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from maturity of US treasury bills" } } }, "localname": "ProceedsFromMaturityOfUsTreasuryBills", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ProceedsFromTheExercisesOfOptions": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from the exercises of options" } } }, "localname": "ProceedsFromTheExercisesOfOptions", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_ProceedsFromWarrantsExercised": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from warrants exercised" } } }, "localname": "ProceedsFromWarrantsExercised", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Property and equipment purchases included in current liabilities" } } }, "localname": "PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_PublicOfferingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Public offering price" } } }, "localname": "PublicOfferingPrice", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "cvm_RestrictedStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStocksMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_ScheduleOfAntiDilutiveSecuritiestabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of anti-dilutive securities" } } }, "localname": "ScheduleOfAntiDilutiveSecuritiestabletextblock", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/LossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of derivative liabilities" } } }, "localname": "ScheduleOfDerivativeLiabilitiesTableTextBlock", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations" } } }, "localname": "ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationstabletextblock", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/LossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfStockOptionActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Stock option activity" } } }, "localname": "ScheduleOfStockOptionActivityTableTextBlock", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrants and non-employee options outstanding" } } }, "localname": "ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "cvm_SeriesAAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series AA [Member]" } } }, "localname": "SeriesAAMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesCcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series CC [Member]" } } }, "localname": "SeriesCcMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesHHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series HH [Member]" } } }, "localname": "SeriesHHMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesMMMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series MM [Member]" } } }, "localname": "SeriesMMMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesNMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series N [Member]" } } }, "localname": "SeriesNMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesNNMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series NN [Member]" } } }, "localname": "SeriesNNMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesRRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series RR [Member]" } } }, "localname": "SeriesRRMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesSSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series SS [Member]" } } }, "localname": "SeriesSSMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesTTMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series TT [Member]" } } }, "localname": "SeriesTTMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_SeriesUUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series UU [Member]" } } }, "localname": "SeriesUUMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesXMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series X [Member]" } } }, "localname": "SeriesXMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesYMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series Y [Member]" } } }, "localname": "SeriesYMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3" ], "xbrltype": "domainItemType" }, "cvm_SeriesZMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series Z [Member]" } } }, "localname": "SeriesZMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_ShareIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.", "label": "Share issuance costs" } } }, "localname": "ShareIssuanceCosts", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_SharesIssuableUponExerciseOfWarrantOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Issuable Upon Exercise Of Warrant/options" } } }, "localname": "SharesIssuableUponExerciseOfWarrantOptions", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3" ], "xbrltype": "sharesItemType" }, "cvm_StockAndOptionsIssuedToNonemployeesForServiceAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Stock and options issued to nonemployees for service, amount]", "verboseLabel": "Stock and options issued to nonemployees for service, amount" } } }, "localname": "StockAndOptionsIssuedToNonemployeesForServiceAmount", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_StockAndOptionsIssuedToNonemployeesForServiceShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock and options issued to nonemployees for service, share" } } }, "localname": "StockAndOptionsIssuedToNonemployeesForServiceShare", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "cvm_StockAndOptionsIssuedToNonemployeesForServiceShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock and options issued to nonemployees for service, shares" } } }, "localname": "StockAndOptionsIssuedToNonemployeesForServiceShares", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "cvm_StockBonusPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Bonus Plans [Member]" } } }, "localname": "StockBonusPlansMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "cvm_StockIssuedDuringPeriodShareStockOptionsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options Exercised" } } }, "localname": "StockIssuedDuringPeriodShareStockOptionsExercised", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "cvm_StockOptionsVest": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock options vest" } } }, "localname": "StockOptionsVest", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "cvm_SubsequentEvents": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEvents", "nsuri": "http://cvm.com/20230331", "xbrltype": "stringItemType" }, "cvm_SuppliesUsedForRDAndManufacturingCurrent": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Supplies used for R&D and manufacturing" } } }, "localname": "SuppliesUsedForRDAndManufacturingCurrent", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cvm_SuppliesUsedForRDAndManufacturingNonCurrent": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Supplies used for R&D and manufacturing]", "verboseLabel": "Supplies used for R&D and manufacturing" } } }, "localname": "SuppliesUsedForRDAndManufacturingNonCurrent", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cvm_SuppliesUsedForRDAndManufacturingPolicytextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplies used for R&D and manufacturing" } } }, "localname": "SuppliesUsedForRDAndManufacturingPolicytextblock", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cvm_TransactionOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Transaction One [Member]" } } }, "localname": "TransactionOneMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "cvm_TreasuryBillsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U S Treasury Bills" } } }, "localname": "TreasuryBillsPolicyTextBlock", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "cvm_UnvestedRestrictedStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unvested Restricted Stock [Member]" } } }, "localname": "UnvestedRestrictedStockMember", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/LossPerCommonShareDetails1" ], "xbrltype": "domainItemType" }, "cvm_WarrantExercisesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrant exercises, amount" } } }, "localname": "WarrantExercisesAmount", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "cvm_WarrantExercisesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant exercises, shares" } } }, "localname": "WarrantExercisesShares", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "cvm_WeightedAverageCommonSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageCommonSharesOutstandingBasicAndDiluted", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "cvm_WeightedAverageMaturityDateOfOperatingLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average maturity date of operating leases" } } }, "localname": "WeightedAverageMaturityDateOfOperatingLeases", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicsAndDiluted", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/LossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "cvm_WeightedAverageTimeToMaturity": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Time To Maturity" } } }, "localname": "WeightedAverageTimeToMaturity", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "cvm_cfgh": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net Present Value Of Operating Lease Obligation" } } }, "localname": "cfgh", "nsuri": "http://cvm.com/20230331", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cvm.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r306", "r342" ], "lang": { "en-us": { "role": { "label": "Title Of Individual Axis" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r8", "r290" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r10" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r3", "r290" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r207", "r208", "r209", "r302", "r303", "r304", "r338" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r206" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Total expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r27", "r43", "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization Of Patent Costs" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/PatentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/LossPerCommonShareDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/LossPerCommonShareDetails1", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/LossPerCommonShareDetails1", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r82", "r86", "r97", "r112", "r140", "r142", "r144", "r146", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r219", "r223", "r229", "r290", "r309", "r310", "r344" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r94", "r99", "r112", "r146", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r219", "r223", "r229", "r290", "r309", "r310", "r344" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis": { "auth_ref": [ "r1", "r52", "r54", "r55", "r56" ], "lang": { "en-us": { "role": { "documentation": "Information by title of series or issue of auction market preferred securities.", "label": "Auction Market Preferred Securities, Stock Series [Axis]" } } }, "localname": "AuctionMarketPreferredSecuritiesStockSeriesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain": { "auth_ref": [ "r1", "r52", "r54", "r55", "r56" ], "lang": { "en-us": { "role": { "documentation": "Title of series or issue of auction market preferred securities based on rights (names are typically labeled by day of the week, duration between intervals, or combination of both)." } } }, "localname": "AuctionMarketPreferredSecuritiesStockSeriesTitleDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type Axis" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r29", "r96", "r280" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r24", "r29", "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD", "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r24", "r80" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r58", "r60" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class Of Warrant Or Right Axis" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r51", "r154", "r155", "r277", "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r302", "r303", "r338" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r2", "r53" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r2", "r290" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.01 par value; 600,000,000 shares authorized; 43,787,825 and 43,448,317 shares issued and outstanding at March 31, 2023 and September 30, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r16" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Modifications cost" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositAssets": { "auth_ref": [ "r299" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.", "label": "[Deposit Assets]", "verboseLabel": "Deposits" } } }, "localname": "DepositAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r27", "r49" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails4" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r337" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Gain on derivative instruments" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r72", "r73", "r74", "r75", "r282" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails4" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeVariableInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.", "label": "Interest Rate" } } }, "localname": "DerivativeVariableInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r68", "r69", "r70", "r71", "r76", "r113" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToEmployeesCurrent": { "auth_ref": [ "r8", "r81" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amounts due to employees, not to include stockholders or officers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to employees" } } }, "localname": "DueToEmployeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss per share- basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/LossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r35", "r36" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r131", "r132", "r133", "r134" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/LossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employees Stock Based Compensation Expense" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r53", "r92", "r103", "r104", "r105", "r114", "r115", "r116", "r118", "r123", "r125", "r135", "r147", "r178", "r207", "r208", "r209", "r216", "r217", "r226", "r230", "r231", "r232", "r233", "r234", "r235", "r243", "r272", "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r77", "r79" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Issuances" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales]", "negatedLabel": "Exercises" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "[Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value]", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Schedule of future minimum payments under finance leases" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r238" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance lease obligations, net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Total Future Minimum Lease Obligation" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2028" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2027" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "[Finance Lease, Liability, Undiscounted Excess Amount]", "negatedLabel": "Less: Imputed Interest On Financing Lease Obligation" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r237" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance lease right of use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r241", "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Weighted Average Discount Rate" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year One]", "verboseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/PatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]", "verboseLabel": "Six months ending September 30, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/PatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]", "verboseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/PatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Five]", "verboseLabel": "2028" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/PatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Four]", "verboseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/PatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Three]", "verboseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/PatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Two]", "verboseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/PatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r45", "r257" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Patent costs, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r18", "r41", "r297" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "[Gain (Loss) on Investments]", "negatedLabel": "Gain on short-term investments" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r17" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r27", "r150", "r151", "r152", "r286" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Loss on patent impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r102", "r210", "r211", "r212", "r213", "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r26" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "[Increase (Decrease) in Accounts Payable]", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r26" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "[Increase (Decrease) in Accrued Liabilities]", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r26" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "[Increase (Decrease) in Employee Related Liabilities]", "verboseLabel": "Due to employees" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "(Increase)/decrease in assets:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase/(decrease) in liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r26" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "[Increase (Decrease) in Prepaid Expense]", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "verboseLabel": "PATENTS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/PATENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r44", "r253", "r254", "r255", "r257", "r283" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Patents" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PATENTS" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r85" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r106", "r109", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r27" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Share-based payments for services", "verboseLabel": "Non- Employees Stock Based Compensation Expense" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://cvm.com/role/StockholdersEquityDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of future minimum payments under operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, after Year Five]", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year One]", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]", "verboseLabel": "2028" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]", "verboseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]", "verboseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]", "negatedLabel": "Less Imputed Interest On Operating Lease Obligation" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r9", "r112", "r146", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r220", "r223", "r224", "r229", "r284", "r309", "r344", "r345" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r7", "r83", "r88", "r290", "r301", "r307", "r339" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r11", "r95", "r112", "r146", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r220", "r223", "r224", "r229", "r290", "r309", "r344", "r345" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r108" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 28.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r108" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 27.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r24", "r25", "r28" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 26.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r15", "r28", "r84", "r90", "r93", "r100", "r101", "r105", "r112", "r117", "r119", "r120", "r121", "r122", "r124", "r125", "r128", "r140", "r141", "r143", "r145", "r146", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r227", "r229", "r285", "r309" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r119", "r120", "r121", "r122", "r126", "r127", "r129", "r130", "r140", "r141", "r143", "r145", "r285" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "[Net Income (Loss) Available to Common Stockholders, Basic]", "totalLabel": "Net loss available to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1": { "auth_ref": [ "r31", "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Options issued" } } }, "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r140", "r141", "r143", "r145", "r285" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r340" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease Expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r238" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r238" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease obligations, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r239", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payment" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r237" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r241", "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted Average Discount Rate Operating Lease" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r67" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "verboseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.", "label": "[Other Indefinite-Lived Intangible Assets]", "verboseLabel": "Total" } } }, "localname": "OtherIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/PatentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r12" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r28" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Non-cash lease expense" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r20" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "[Other Nonoperating Expense]", "negatedLabel": "Other expense" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingGainsLosses": { "auth_ref": [ "r19" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other.", "label": "Other non-operating losses" } } }, "localname": "OtherNonoperatingGainsLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherResearchAndDevelopmentExpense": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other research and development expense.", "label": "Research And Development Expenses" } } }, "localname": "OtherResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r23" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "[Payments of Stock Issuance Costs]", "negatedLabel": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r22" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "[Payments to Acquire Intangible Assets]", "negatedLabel": "Expenditures for patent costs" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r22" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "[Payments to Acquire Property, Plant, and Equipment]", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name Axis" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r1", "r165" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r1", "r165" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r1", "r290" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r98", "r148", "r149", "r281" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r21" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from landlord funding of lease improvements" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r93", "r100", "r101", "r107", "r112", "r117", "r124", "r125", "r140", "r141", "r143", "r145", "r146", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r218", "r221", "r222", "r227", "r229", "r270", "r285", "r287", "r288", "r300", "r309" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r50", "r89", "r271", "r290" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r50", "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r179", "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r179", "r246", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r343" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party Axis" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r244", "r245", "r247", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": { "auth_ref": [], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.", "label": "[Repayments of Debt and Lease Obligation]", "negatedLabel": "Payments on obligations under finance leases" } } }, "localname": "RepaymentsOfDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r66", "r91", "r346" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r4", "r57", "r87", "r275", "r276", "r290" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r92", "r114", "r115", "r116", "r118", "r123", "r125", "r147", "r207", "r208", "r209", "r216", "r217", "r226", "r272", "r274" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfCompensatingBalancesTextBlock": { "auth_ref": [ "r14", "r298" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes disclosure of these arrangements and the amount involved, if determinable, for the most recent audited balance sheet required and for any subsequent unaudited balance sheet required in the notes to the financial statements. Compensating balances that are maintained under an agreement to assure future credit availability are generally disclosed in the notes to the financial statements along with the amount and terms of such agreement.", "label": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfCompensatingBalancesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of total estimated future amortization" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/PatentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r61", "r62", "r63" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Schedule of equity compensation plans" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r26" ], "calculation": { "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Equity-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Remaining Options/shares Under Plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Options Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Options Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r59", "r65" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Stock-Based Compensation" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r13", "r53", "r92", "r103", "r104", "r105", "r114", "r115", "r116", "r118", "r123", "r125", "r135", "r147", "r178", "r207", "r208", "r209", "r216", "r217", "r226", "r230", "r231", "r232", "r233", "r234", "r235", "r243", "r272", "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/LossPerCommonShareDetails1", "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited", "http://cvm.com/role/StockholdersEquityDetails", "http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetails4", "http://cvm.com/role/StockholdersEquityDetailsNarrative", "http://cvm.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r114", "r115", "r116", "r135", "r256" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cvm.com/role/LossPerCommonShareDetails1", "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited", "http://cvm.com/role/StockholdersEquityDetails", "http://cvm.com/role/StockholdersEquityDetails3", "http://cvm.com/role/StockholdersEquityDetails4", "http://cvm.com/role/StockholdersEquityDetailsNarrative", "http://cvm.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Stock Compensation Plan [Member]" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "401(k) contributions paid in common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "[Stock Issued During Period, Shares, Issued for Services]", "terseLabel": "Common stock issued for service, shares", "verboseLabel": "Stock and options issued to nonemployees for service, share" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited", "http://cvm.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r1", "r2", "r53", "r57", "r188" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Option exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "401(k) contributions paid in common stock, amount" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "[Stock Issued During Period, Value, Issued for Services]", "negatedLabel": "Stock and options issued to nonemployees for service, amount", "verboseLabel": "Stock and options issued to nonemployees for service, amount" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r13", "r53", "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Option exercises, amount" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r2", "r5", "r6", "r40", "r290", "r301", "r307", "r339" ], "calculation": { "http://cvm.com/role/CondensedBalanceSheets": { "order": 26.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets", "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r59", "r111", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r225" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r236", "r251" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r236", "r251" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r236", "r251" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r250", "r252" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type Axis" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r37", "r38", "r39", "r136", "r137", "r138", "r139" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.H.3)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13728-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7,9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r291": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r292": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r293": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r294": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r295": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r296": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 54 0001654954-23-006371-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-23-006371-xbrl.zip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
X71:_QV6 X^J&)OI*MF?$K/3?/10!$'J. M(DE0)4.I+5%*1R$V)'J^?D')(V8.HWZ91/XU>D>K^(T@JLVI7E\76+IFFI+$ MRW"+JCF\_E]US!X-A2F:1=E+D_/@*463-$5KW)&][9\^6;BJ H3&N/,#DTQC M=/V_]GA\#7/2AXK;3W8=8%@.DL7+M(DH.&&)#02NN#9CK&KT"L#:I?X77IRL$U" M #[$279&#XZ[=@@MHB^/O+4!,M7 DL2DU62A; RP4V0M2T)?X(I$?#'EL"L# M#,WTD&SW3/QLG\(0&]1Z+/+ZHS6M.- \S97.CMAJM3I%U.F!NIZ%P_!DHV+9 M>W%IGNZ[0SO'\4$Z0T+)DPUK&;ZB97P'UYND4K-A5@&^B0L/C7YN5&=XVNX* M%P@]N-H]P;M,0KBJV!DH)0%45<,:FFY?!Z;;,W<\ SV7+'F*_/0H4*$_-FD! M**ZB!K*EE6X^#?A =GO$KM=4%5WTEF;M@ JBL0/X3$WFI902\_B]6)W_A+' M?^P2(BQ?CM(AG%@S*LW2W"V \5A1;4FR1C6T6C<'F8NKG46!*J[=>;[4A1IK M:&TU8!J.6[[QE%\P_,AR:?2I\#H8P6)OFMO M6+Q7QU@6;[?OG,.72AE.#EPA%D';A&2?B>N&)"=+E'I) M^%9M@F[;&M!<.RBO&M^%#-F +I4?[16X,O(,^^O*1^P71!4$O"SS%,]' _9$._F6RD%> ;T/+$):4.UU@A>T?^:9_Q#IFLPW]F V%W&U)(Y7:#)0=7%8GR#I:4 MKHT#?8QL*(DK72NI5MF8>F-FN'GTFK'0Z.V3#NT"7P],6=[,$S7D*DD9;F*] M9@3P/+#2O#DP]FPKD,1:(6ILG7(QW$Q[+7#7ON+2ID%@*(H/)?$[$CJLCM@8 M;NJ]YLAKGXIIT1ZPQ@:412L2.:R.R!AN+KX6P.M>)FG1'IZ>P?C_+U8G9 PW M.5]#729>K8A1C_OMFXYM P^JGBTZ[DVT LDB1E@*OWY"PV98,0ZJV6#X2'+4 M!IYGZYXDODK]C9Y&T/M,^2?(_,A,'&;4V2$%IP@38)&T\-+@]AB2MI7&[/4- MA@DQ5U^]P.2YR@FCHC!P V3+\N95*S8IQGLV4K&!M\5]A,1K\ZZK['K ,"Q? M%M? 'L38#/1I&.[%UL/;.$T?4$)2U\71 H\SQ+B9&9^NB+?SQ6+T,'W,+GR>/4['W-%.81%A*!%0&IWX%K*H!@D#U T'W+Z>=^@+3T".AW.%J0_Q. M&Z.J: ",-<<>2^)I4RL)ZA1KBK33ZEGECSN+\)1"9#9-WO'8)UX_RW@WJ]:Q M]\=+O,)?34_Z5NFSE+N2T'^>A,.@N\%HMVE<-[@+NTB. M.")@3W!FW:TXM[9O#P2:#3A,RB#\F41]S-)N=DP0]XMCC2J>>>"D #SQ'M:+H32.+74\$P6QIE*,)S1$_P M4NN3!35\1PODD>C$$*5;C1;YV]7X]6VSWFFII97^@]X .]/N&3\* M]TI8L4 MY1@DE^!$<#9F>@]Y4F37U026$_B6)#XREY!D@R%$8>D,B0_FF2-]RDHN>50$ M(.3HY0 7F21&(:YT<*5C.D-:@Z?H':7XU/N(_S<)/7+^)5HNBV]F%>#IIF=) M%@P#DSGV#M/&#@U EY,DUQLW!3] MN<$M3=]Y;R*M4WUR\?1E,?WE:7J_'$U_[?%.DKHJG?:8OA"=E@*:X?N!H+1( M+75"!05C170>'A:7/'I@#F+H>B!2'$T2TU<%P]QZX Z*<#WP9%S5OY9240$H MFA](ET")1S@U>+I%^YY#/G5*4V458/MC92S+7E_#.Z^P3J#)):[*8SH=S^[X M:MB^:LMBRJAEG$=0)\#.$&Y=N %3. 5*):$4"/W?T4Y\/R04P-7VAG >%*8)G5IF%8 "!;J2>$XT89L/ M5:=$]C4"J!O2M)+ \0W#E"2 J!W=%#"GN>BK;0J[OY#_<6&*_O/_ 5!+ P04 M " !W@:Q6;.&>K52U ]6 H "P &-V;5\Q,'$N:'1M[+W[=^)&\@?Z MK^@ZNYN9O_Y6=4L@L,#B M(6A)G;/9V$:H'_6I9U=7??E_OT\LZ9FXGNG8/YVIY\J91.RA8YCVTT]G,W]4 M:IS]OY=?QCX\!4_:WH7Y_:>SL>]/+SY]>GEY.?\^<*USQWWZI"EJ^9-I6Z9- M_OCZ<'LV?]R/?W[QZ"??U6UOY+@3W8=9X)NJ)44K:;7(2TH>&2Z]"'X_?W*> MWWU/HU16P_<,9ZX+JWN=OXC.)GQ3^"E\4=."KRP-^5*F,U>;S>:G[[@EX7N_ M>V;<@YJBJ)_^^';;&X[)1"^9MN?K]I#,OP43_VO] /AI^.B;)R/;KI0_X<<# MW5N\&3XU-SS_9B;PJ>$O[TKPR+\PLPKN8Y%%G@9Z=Z /AU^LK3BH3.S?7<=#MF'2U^8^>[:R30_P:?A@Y[K MEW#Y,3.9?[3T9MBOE2_$;R=\1RDI:DE3(T/%#K(\<:_TI.O3V'W!#Y:WY7E! M5/CY?.A,\/.R4@8>!BE$=./RBV_Z%KF$C_^C*G^? QM^^<3^].7_*96NG2&0 MW/:E*Y?H/C&DP:N$LN&;[OG$+94NOTR(KTLX1HG\/3.??SJ[^ 8KY+GOUJ$/5#2+?/)OOCOS//-T>OG$7SY M0E6FON2;$^))-GF17&>BVS!YPWP.OOFC87I32W]%&)//V[SF\X^2:?ST(R[H MNO/;CY=?S.\7.#'BLA]-PR V_1%>?<>P+]GZ!&8+/'?1MF&C7J]@>:YN=6R# M?/\W>0V6_-U_0.:X@7&0(B45B>T[N/LEI8PR]%*!?^I:M5PK?_FT-,3Z$5M M"P/I<6/I3XE'DI@,_^D,Y/[%P 'NT>V1;H%\NZ3_23S\%97H_HWI#77K3Z*[ M;=NX!E@D7W.II#1+927QB"'^V)#W\*ECW,#?O.1#_JKM.!HN<,NQ\.2;-;)-]\-B[OJ?/PWP-,C0G0-J?SCIW-X"T\[D^[,1^V/%E[L=.9<^-YT MZHUZ0ZMN.9U[T+($N-+@#T++4SLDBK1=(!0WG?U1=(A9' A!QYC*@7<%K(Y0 MJ7S5+69")]H 0.H^F*#CZM[X7C>-!V(AO_2=&]/&&=P2L/SC9;X:D?D:F]-_ MT'#JHZ/$!NC:Y!N9#(B[<;)JF<[V/&:^GY8-#THC\**(=_D%W9(+CSH_\%Z) M>C07:$S^]*-G3J86^3'XVQ@-\Q]A9J70VCO_[AE@WWQ:?@4;+3H$_=5S9B[] MC?H]%\%&H*FT4?D%CQ-J%86_F0;^/C*)*]%A2:S3>=7Y][(]M/KER_!/RV^? M4H,@_ V0Z_IHCUPNIAA^;_'9?)I&^&BP@L40[)/P]W"03TO;L6%WX'V5R.Z@ M\_V?@.G^TYL-/#"481GM9_B_ "LI[UVP!>0)C1OVJP&#?9]:YM ,YB 98!O; M+&P12HB5R:)%W_IN>F>7:QY@;_KR*7: ^0;.Y[$M28-]34A2W/:T2%HI:75! MTJ.3%+?]8"1=)\P?[6<"SBWH!<\'^]T/]"/?9&W!&PS3FOGF,^F1X]#:V80 U<,=NMTYM-(7G?4UET;5+P7VH=?7^-?P*"!VG+CKJ0&#S6Y$-<. M+,1C5)R !V?P.*&.7R<]NE/<0J_@<%C:A2))!T'^XY'_I-Q/W> H]_/F_ZAA MI)4?YKC5;<-R7(-/[O!<_Z*/!Q_=4<C+()4ZTG% M#GK]F-T//SFX01$;6^*,'J%BB(6D2NS8#D\*@BW T-IRPIK=X:* M$6>"%J<5;NLL D&7+-@'[VBHMOOD3 BGIL+\L,O2[3M]$B';TK1SI8SF3*>H M@EY;\Q?=M%/0JQRA5UG0*_$!0E)Z'5H>KE-J@EY\ZB]M27_!SUJ#TNNJW?V9 M$-?_-W$]G]A\TRW(5KB';7N-&![>U]?H)PNJQBZ.!^H&%#B8ZP6*5@LY\ HV M9&;YIOW4>G()P;5P'I)]RX[KUY"2S1]L8"K^ER (QTZ8($[6--DZ3TQ0,C,^ M6HS6NG/L7V>ZA3O*3L^#8S3<(\[)V'K176,Y*I)@-;PKLAAN$_0Z,0.N$#/_'-Q2O+-T#B_MWW05R^EWWP7P:^PL"+JTA33&3-%8= M;'#J8H8MO-?+ ?7"1>21]]8=Y;&5W]WE@'SA(O)XLD>-AAASE*W\:I@#\H6+ M2%-X:B>RTY$W-=J\4V^UHQZ?M]T]R_B+PHFS'U1 M5CJ!+66%J.'2PY>?=731;TU]8%IT7_BFZF+*'=OS75KSY\'T M_EJ0<,.B4CJUT YUVAMS_"Y(Q->!_)R+WJ2L8 B)';SP39X](F31Y:7&2X<] M 4QP2"2(ELT 2PPK"K>.-SX3%,DH$ST\Y(!DX2)RP42"(IEC(A'>YXV)!$4R MQT3?ON6 9.$B&6.@/W) L#]RQ$""'AECH,?' M'% L7$0N6$A0)'-,E OO-4@,S=OX9I(.X%\L_C3KV$&?Q3++. M-)L7DBW*<%!".M5%,KLG5*,/Q-=-FQCAM3^^H4>;JN%WVG_/L.DC*$W'AE^] M98T:OZC48)A.RF!(H99AF"CK= O[9'7L*WUJ^KJ5"T)M7%M&Z15I39@+&KU9 M#^]TV5#(44B]7-1\W$1:P7XY(ZC0?WD@]'(8E"\;^V!QQI58K] VW$6"UU!( MR)ALT4LH>?Y.5(34.^EYRPII#UVGFQ.MS?'N"&52$#806BB3!%UI#B;4%*\M MPU8I).1IMN@EQ"(W=.&D)6Z*!38T$=GGO 3**H6$.,\6O80X/S%=-E0?%5(O M%Y5)-Y%6B,N"$%K(V2P1=+ES$%\V]J%[R*DBLL]KOFP1QFJ.+0]N.64 M+H6$TL@6O83L/S%=UO=9X4"T[ZKL#AT_C;DGPMONG/ 634QTF;?=.6&H5N/1 M4#ITS@<_3)'NC=MJ26EPMTB?A3^CM]_\R[:OM=[\[J \^B'6[T/QK]?>:=A/L..19^\FTV(J_N.N^,J MWGP?_WA-;&=BVG&O3;J:I5=\6I[]ID7?PXO6;.$4?MR\@9_,[Q''@3KGA 7%^;YKF,_73[>=?KM:ZG7;_7;O2^?@K\>9^Q>^^KQH=/OM'M2 MZ^Y::O]Q]4OK[N>V=-7]]JW3ZW6Z=T>>T.^Z-P97UG=L6;H^OSJ7-*5:::8[ MB=.0_8LWU>T8'FM,_;/+F^[#-^D+<+_MV%3 F4,IT /9+2I/MV99.NHP0QB M7EP[0]J "TOOG%W"H[]2B;)X)^PGSN+RN/O[ =OR25V;?$QYIP^U?[_.P.@D MKO7Z0*:.ZY])(\>=Z/Y/9R8,"O;!Q-#[[%UUY?Z70F8N0\<*ZEEJ?L@J57I@_%1 MZMZDN\G]7]I21(K,)4CKJ@]C2VJS7,D!T]XXKN2/B?1WB 2)F6<2.!G$D.8\ M?2C$W=.WMYD'LX2W"P.C&?#BL:&_OA*P8NRS2V"HX5@JJ[*$KXUA\F.(\.Y# M1MB9]E"C\;AM^+ER('Z6^@^MNUZ'KZYWH[I-I7\!J-_@6 \<%YZ8$1L@0K+X+Y?/* )%MLLC( M#UY:PI\O])GOA']PL;8M^PMS4&K@GTA#8EE3W3#@U3^=*5%_)1Q_3.@7U2K. MR)/I(=/Y=_ )0+!]6^I==< !> #1U.I3 M#V M- +C<;KLV*W;W$/A:&7 M+W".5TBH^\*XI#7$^.X44T7QVR42O6?*2/Z MH*#MV$/'!A1 MA"VV,@Q\I+M3JPC/.RG[^O=.$$$=4G*&FJE1*2E-M5:N5!)0*;G@28=>%(,2 MF# .V#"N]-^9:WJ&2;OT2F84K%'"'A5%J0_VH?/0^RBU)U/+>84M6"9J8,D< M67 ?UT4,QC@L>[0,PR6>%_SGUK2)"JRA:4WIJ^/8!/Y_9I%GW356F43>/WJT M;@;:V65O9@+>&XIV(E&+W#HQL_9\YI?KW M4M/41APRTH\TKC!C,#W)&4E3%[;,G.J61+Z3X0PKC\.?03[A(= QQ$(RB'XX MF/Q >+9[YP;7[T MX#&+3'&FDDVG*J->MF9H4DLZ;!.LWB!'0<*!QIC_VSPO5_&;L8JO!UAW3=^$ MU[AT.XA+#&DZ<[T9[ N&4> )JJ%5[]3[)B\1_(M^9O3\!E0W;MO4X&CO7!^UCX'<&0S1PD[>_# ML6X_P1]LZ?>Q"7]YF',\#Y[2WMHFD&6OJC:@[,'BI;!:FK/Y5N/$.C\'@P+/ M.Q5P"F,4V*;?OHG=>8NCD&%HX/.-+4W@T]",OONSUY9:=#S=7K^5:3FUR53] M_J?+XO^/__\IGRAU; -#,$0:O$K#,1G^)4TP]^)E3&B@"FV]A9DL?5 _2F/= MDT:F!5:B;EE@-.(!*1J/?\],-!W!8AR0X %XY]QZ+&/T2ZWB865@0T9,S[EJ M KL2/\;S1,F 3T&;XZ-3EPP)U>VJ)M&S;4_Z .\#GI2\&6@R;^S@L7MX).B/ M=7]U[B_Z\BQQBNS+P1H^2KIM2!\T7"+,'1@;/A[\%Q: C],GX3LXB> U>%3L MT3G0.>J>+S45R=!?O;0/&P_DG5_-7!?6P ZY41_XNC_SSB[_1)]W)2 0I*Q( M=XXT/^W._H%J OB["P@A] $2$]/W 4/@, [19X476-:K1)Z)^RIU4 GI0QH^ MN-9]G9W3KG#'XAV(N*GC^2L^U\,,OE11JL@+ .&9Q8*DO5)?^H#[4O^LE;7S MX %_;'HP>7T*(W\\"->XZ[F&37T^[SE;$._CN90-U$=(A!0*F$"@?IW0!W3I MD@76')'T(3C.F$P-8$"BNS(@(?:O$NQB*?8#;P+L J.XH=0!0DZFNOV*"@+> M!F(5#<!S.7Q@[?3"%R'T@V?73#5\TK09(X,_4M)"K1=5=1=I/[SN00;OLM0H5M300.[ \4$^OC!EJ:\XI*F-C14]V5%M=;\4Y8(OQ[ M:A,Z8&J5>P5[_.2XKS$^)7V(;OPP>(BZERNR](919KW'GOIVA'KQJ(/VF&AF MZ)S+9_9K('J/.I\#88(NZ^O,,VWB>;NFCI\PQRJ==Z9.O7:\\LXB@L*E_$Q7 M'IFZA.8MY:_@PWOTT=-?P)#R_ M-XUUIW3E#_K'.%OSO. .C#<&DW3N:GP \E$_ K81S/2E^--FF_UCVK$=<$,/ ME7W1PS7O*0[6WE((7>+:$1&UE1,3N8B:_?->>L*+> S.L@I^L,DF>.><2^SZ MN-2=^51" H$+OSEX)8R' ]W@]#7[1XDW-%P(2XD*XI7*$6^#ZXMR00RC$8@N M7]BS9Q/#\0TR-,$3.)."'[R?SCIW-V<2WONG X:%$BH5N:Y6Y%I]?B>'H+]) %#M84*]BE*,+J7KRO$"G)WVS&GKIQB-H(_CX=C-W% MMFT1I^FW_^B7.G?7[;L^(\C9MM+JQZG^1$H#E^A_E?018.A"TJT7_=7[<0M? M^,W,<^'MK*DD$!!-]W60/\&(ANE-+?WU HQ@FE]*"Y3TNU=GE_W6U]LVWNV\ M@CD F7K224H!I'VD%*SEOO70ESK23>>N=7?5:=U*('J[#]^"ZVU'7_ )[-S% M[:65:(?O3 ]A-75\,I'4\R6S:>A8"*F?SK2SY6DTE.-::JL66H)M.#2OWH,X MVSK<'7_E['"[=3H"I;JR];O[>: /_WIRG9EME(9X"?#BA^&0D-&(GVU/ASV_ MZ-+812OSAX&'EKMM$!MC45]U2[>'!-PL0GQ/TGUIN92$]&%FZS/#](G!\F=Z M9.JS2IMEA3ZB@>+0W[DP>61>6[4PDT)A1/_A!PIGF]E&8/T]K#M3-0KV>2%8 M&FGI3@F[?[/(\?+,[V$B#0OQKC #RPU8!,DH_",VUI*^]*X4"T;V)7\''5[HWEFXLYV4[TXU[/FH( M/A+*,(.\:CL^GES=X7\P6V7!MS?S7)<%!Z\4[PC#KSPSIJH(SCRMADL;PJ86 MQ+"U\S?H.REOX<2^Z;;^1)GG1T^Z-KWAC!6)1*76LG7KU3.I7EQP&W(@2TW# M9QZ(-[-6/4GNF$Q3\\-D>>*,0AW^8(6_(Z=8 M#G99\"1]X,QH,*L$^*_PAO\*]9# >K(\BOU[ MUQD28T;[FA0%V\* 2KA7*:$QS)V8HQ+#V"S=HL-0&%=2-9];+.#(D=3VN37H M<6:/=J0<6T^W"#7.@RAQI'(&BO5'CQ9YHM*=&!S*=A'^S3TSU0)FJG''3#"S M]O>Q.3!]P1F",SC8J[0A[YU=]N#%NL^GH5_G+KT_0WGS*WFK PO0'LE>E=[D MU<>2X!2I]E_()()1EF*N#UD-4W12:>"?@A4?Y!H>JZ5GTX-+*$::NW[?OO;U_8#O7/! _%.7:ZKU>M1G@*W[UO5UY^[GZ-H^%T=8Y(&^&J_T%58#O]KGP^-=Z_&Z MTV]??^1!]7!.N3RL>#?M?J! 9U"O68(=)[YWL2&X^<\C:I\ :/1J1%P_*6+ M33_VTO<]_DB',==6BJ.W,?"@>H@_8#'Y9]UB\=[3[V7,R/'*-7X^_U@'QJTU M-BVDC2M['?+?]*=UVL M/?F;;LU(PBI42J0&U6/O&I/=9:52DR.==R,%J+BCIL#1,H[*L3C22DJS5%:. MBB--DVMU35;+#>YPM.]A_)$E[+U+IKII2.3[%*_5\"I83V89')R)*ML(XX Z M;4:_J5/II^OJ44,KYF-8&-ITR9.()U?9JHED=K#Y\E%2+1'H-F- MXSY<@PWT+4JJ/7E+E1O-LEQK\,==!1TY;>35DXCQ8R /9+JBRG6URAWR,F9R M7Y.IXYF\Q3#>JVMY>IXZP/G8>\S62"KF QJV:"1Y3\8J5^4:GI^]PU6Q9VA% MDK0"J N@-I-JA?>!^C_B.H;NC3=BM)0)>.Y>IR^/C,(-/^3S**6@(Q>)Q'P: MEGW'URUIN'28S<-N\0S+O16NJFP3MSV(7:AJD16\ZL>9QU70D5,'F;I- MS/8@(-.J<@4=8 ,_BM-D\([ U,L;RW#TSXGH,TQNR1* ME%ID'3)*W5NZ[;=LHQT2ZVX/;E%EM=Z4:QQ:-@4=.77,)4J12AESC4935C3^ MS (^K>E[':MV =4\WQ."^2A,DBBU*>)QPL)OS6=B=&Q?MY_,@<6,&&\?-FEJ MLE96N>.1@HZ<.N02)2FE"SE-!<@I_$&.3\N9S\S4'+*&ME4VP5(.W^[IVV6U M*:L<\D)!1TX=8ULE$VS V($21+D6L4>S?#-[J4ND72-/)3HJ3'0;Y\ZQ]\T/ M4_ RV/MA#AXRLP6">4%PHI/'8R&X5I&U!&S$WB-LJFV$_Q%45N:J5Y;KR_LT"'A G[#NA_(NQT8+$/,N3 M=.V[VT[K:^>VT^^T>U+K[EKJ];M7__ZE>PN:I_>CU/[UL=/_DX?=$S MPD8+ M$O,LB?*T!P)L1=AH06*>Y4FZEDW8W,$R]8%IT1;GO'1X$+#,_48+$G,G>8X4 M,Y?"?UD3F]9P")/P/6FJOV(KX.-OV\J$$E"/SVX#VE89R^&^W[-MW[_*;J,A M-]53)\MM3TM.IL$II+;*2#XTI&IJ0]::"M^0XM&X>RMBW1DY9745_TR@P=.II$Z++>KHW9H6#8JFEPY>3&70PKZ MT]C2US,B^8Y$)E/+>25"T)^2H[:JD02$ZSOMD&S[MBU2FK+6.'5YPLP@@9-I MI [(K2HH'120E;HJ5QJG[CR7?3N>UDB)QFOE>5'CJ>/BEO(08%MHL3'-&%;+Z/6>#^@R -L1>5E M<:A3C(T6).9.GIS&&%UNJA$Q2GG8/YZ!NK]JWJIDW.&B=%6YK*IRLRHZ:7(R M=R-7"0CH* C%XG$&;#SEMMM. ,82$=9 MS,I08D'WD\<@18P_5-C;UJR<=TD(E??KG6,/]ZVR(S>J55EKG+JV:V9@P
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�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end